

Structural, functional and mechanistic insights uncover the fundamental role of orphan connexin-62 in platelets

Article

Accepted Version

Sahli, K. A., Flora, G. D., Sasikumar, P., Maghrabi, A. H., Holbrook, L., AlOuda, S. K., Elgheznawy, A., Sage, T., Stainer, A. R., Adiyaman, R., AboHassan, M., Crescente, M., Kriek, N., Vaiyapuri, S., Bye, A. P., Unsworth, A. J., Jones, C. I., McGuffin, L. J. and Gibbins, J. M. (2021) Structural, functional and mechanistic insights uncover the fundamental role of orphan connexin-62 in platelets. *Blood*, 137 (6). pp. 830-843. ISSN 0006-4971 doi: <https://doi.org/10.1182/blood.2019004575> Available at <http://centaur.reading.ac.uk/92331/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1182/blood.2019004575>

Publisher: American Society of Hematology

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

1 **Regular Article**

2

3 **Structural, Functional and Mechanistic Insights Uncover the**
4 **Fundamental Role of Orphan Connexin62 in Platelets**

5 **Authors:**

6 **Khaled A. Sahli,^{1,2*} Gagan D. Flora,^{1,3*} Parvathy Sasikumar,^{1,4} Ali H. Maghrabi,¹ Lisa-**
7 **Marie Holbrook,^{1,5} Sarah K. AlOuda,¹ Amro Elgheznawy¹, Tanya Sage,¹ Alexander R.**
8 **Stainer,¹ Recep Adiyaman,¹ Mohammad AboHassan,¹ Marilena Crescente,^{1,6} Neline**
9 **Kriek¹, Sakthivel Vaiyapuri^{1,7}, Alexander P. Bye,¹ Amanda J. Unsworth^{1,8},**
10 **Christopher I. Jones¹, Liam J. McGuffin,¹ Jonathan M. Gibbins¹**

11

12 ¹Institute for Cardiovascular and Metabolic Research, School of Biological Sciences,
13 University of Reading, UK

14 ²General Directorate of Medical Services, Ministry of Interior, Riyadh, KSA

15 ³Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

16 ⁴Centre for Haematology, Imperial College London, Hammersmith Hospital Campus, UK†

17 ⁵School of Cardiovascular Medicine and Sciences, King's College London, London, UK

18 ⁶Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine
19 and Dentistry, Queen Mary University of London, UK

20 ⁷School of Pharmacy, University of Reading, UK

21 ⁸Department of Life Sciences, School of Science and Engineering, Manchester
22 Metropolitan University, Manchester, UK

23

24 **Correspondence:** j.m.gibbins@reading.ac.uk

25 ***KAS and GDF contributed equally to this study and are joint first authors**

26

27 **Short title: Role of Orphan Connexin62 in Platelets**

28

29 **Word count: 4735**

30 **Abstract word count: 183**

31

1 **Key Points**

- 2 • Cx62 is present in platelets and its inhibitor (⁶²Gap27) attenuates hemichannel
3 and gap junction-mediated intercellular communication
- 4 • ⁶²Gap27 inhibited platelet function, thrombosis and haemostasis via upregulation
5 of inhibitory PKA signalling in platelets.

7 **Abstract**

8 Connexins (Cxs) oligomerise to form hexameric hemichannels in the plasma membrane
9 that can further dock together on adjacent cells to form gap junctions and facilitate
10 intercellular-trafficking of molecules. In this study, we report the expression and function
11 of an 'orphan' connexin, Cx62, in human and mouse (Cx57, mouse homologue) platelets.
12 A novel mimetic peptide (⁶²Gap27) was developed to target the second extracellular loop
13 of Cx62 and 3D structural models predicted its interference with gap junction and
14 hemichannel function. The ability of ⁶²Gap27 to regulate both gap junction and
15 hemichannel-mediated intercellular communication was observed using FRAP analysis
16 and flow cytometry. Cx62 inhibition by ⁶²Gap27 suppressed a range of agonist-stimulated
17 platelet functions and impaired thrombosis and haemostasis. This was associated with
18 elevated PKA-dependent signalling in a cyclic adenosine monophosphate-independent
19 manner, and was not observed in Cx57 deficient mouse platelets (in which the selectivity
20 of ⁶²Gap27 for this connexin was also confirmed). Notably, Cx62 hemichannels were
21 observed to function independently of Cx37 and Cx40 hemichannels. Together, our data
22 reveal a fundamental role for a hitherto uncharacterised connexin in the regulation of the
23 function of circulating cells.

24

1 **Introduction**

2 Connexins (Cxs) constitute a family of channel-forming proteins that are distributed
3 widely in different cell types.¹⁻³ Connexins oligomerize in the endoplasmic reticulum to
4 form 6-membered structures known as hemichannels that are transported to the plasma
5 membrane. Hemichannels on adjacent cells dock together to form gap junctions or pore-
6 like structures (~2-3 nm) that facilitate contact-dependent inter-cellular trafficking of
7 small molecules (up to 1 kDa) between adjacent cells, enabling coordinated cellular
8 responses.^{1,4}

9 Gap Junctions and hemichannels have been studied in various cell types, where they
10 mediate stable cellular interactions and through mediation of intercellular signalling
11 coordinate synchronised cell function within tissues.⁵ The cardiovascular functions of
12 connexins are well-characterised, from cardiac myocyte contraction⁶⁻⁸ to control of
13 vascular function.⁹⁻¹¹ Notably, connexins such as Cx37, Cx40 and Cx43, present in the
14 vasculature, have been reported to contribute to the development of atherosclerosis¹²⁻¹⁴,
15 a process in which circulating inflammatory cells are implicated.¹⁵⁻¹⁷ The reported roles
16 of connexins in regulating the activities of immune cells including monocytes,
17 macrophages, T cells, and dendritic cells, in addition to platelets, are therefore
18 particularly pertinent.¹⁸⁻²¹

19 Platelets are regulators of hemostasis and aggregate at sites of vascular damage to form
20 thrombi that prevent excessive loss of blood.^{22,23} Increasing evidence indicates the
21 importance of sustained signaling between platelets within a thrombus, to ensure
22 thrombus growth and stability, and the importance of direct intercellular communication
23 between adjacent platelets.^{24,25}

1 We have reported the presence of Cx37 and Cx40 in platelets and through the use of
2 selective mimetic peptides and transgenic gene-deficient mice, demonstrated that both
3 hemichannels and gap junctions are required for platelet activation and thrombus
4 formation.^{26,27} In addition to Cx37 and Cx40, we observed notable levels of Cx62 mRNA
5 transcripts in megakaryocytes and circulating cells such as B-cells, T-cells and
6 monocytes.²⁶ Very little is known regarding the properties, function and tissue
7 distribution of this 'orphan' connexin, which has previously only been reported to be
8 expressed in mouse (the mouse homolog is Cx57), in retina and muscle cells.^{28,29} Given
9 this, we explored whether Cx62 has a role in platelets.

10 Using a newly designed inhibitory peptide (⁶²Gap27) and Cx57-deficient mice, we reveal
11 the importance of Cx62(57) for the regulation of intercellular signaling in platelets and
12 within thrombi. Furthermore, we demonstrate that ⁶²Gap27 inhibits platelet function by
13 stimulating PKA-mediated inhibitory signaling that protects mice from thrombosis.

14 **Methods**

15 The preparation of washed platelets, immunoblotting, immunofluorescence, and platelet
16 functional assays such as aggregation, dense granule secretion, fibrinogen binding, P-
17 selectin exposure, calcium mobilization, clot retraction, platelet spreading, thrombus
18 formation, and tail bleeding was performed as described previously.^{26,27,30-32} Detailed
19 descriptions of reagents and these methods are provided in Supplemental Methods.

20 **Mice**

21 Gja10^{em2(IMPC)Mbp} mice were produced by insertion of an indel-causing frameshift
22 mutation by the International Mouse Phenotyping Consortium (IMPC) at the University
23 of California, Davis, and mice obtained in collaboration with the Mary Lyon Centre,

1 Harwell, UK. Phenotyping of these mice in the IMPC pipeline revealed normal blood count
2 parameters. C57BL/6 mice were purchased from Envigo (Huntingdon, UK).

3 **Statistical analysis**

4 Data were analysed using student T-test and if more than two means were present,
5 significance was determined by one way ANOVA, Two-way ANOVA (*in vitro* thrombus
6 formation assay), Nonparametric Mann–Whitney U-test (*in vivo* thrombosis and amount
7 of blood loss in tail-bleeding assay) and Fisher’s Exact test (time to cessation of bleeding
8 in tail bleeding assay). Data represent mean \pm SD and $P < 0.05$ was considered to be
9 statistically significant. Statistical analysis was performed using GraphPad Prism 7.0
10 software (California, USA).

11 **Results**

12 **Expression of Connexin 62 in Platelets**

13 The expression of Cx62 in human platelets and the megakaryocytic cell line Meg01 was
14 confirmed using immunoblot analysis and the expression of Cx57 in mouse platelets was
15 also observed (Figure 1A). HeLa cells are devoid of other connexin family members³³ and
16 were confirmed not to express detectable levels of Cx62. Immunofluorescence studies
17 performed on resting permeabilized human platelets revealed Cx62 (stained red) to be
18 present in a punctate arrangement inside platelets (stained green for GPIb) and were
19 redistributed towards the periphery of the cells upon activation with the TxA₂ mimetic
20 peptide U46619 (used at a concentration at which platelet shape-change is minimal)
21 (Figure 1B-C).

22 We also utilized super-resolution STORM microscopy to determine the subcellular
23 localization of Cx62. In comparison to the resting platelets, Cx62 (stained red)
24 redistributed on (or near) to the plasma membrane (stained green for integrin β 3) and

1 appeared to be arranged in clusters, thereby, increasing proximity to integrin β 3 in the
2 plasma membrane (Figure 1D). Treatment with secondary antibody alone (in the absence
3 of Cx62 primary antibody) was performed to exclude the possibility of non-specific
4 staining (Supplemental figure 1A). To further confirm the translocation of Cx62 to the
5 plasma membrane upon platelet activation, co-localization of integrin β 3 subunit and
6 Cx62 in resting and thrombin-stimulated platelets was analyzed using the coordinate-
7 based colocalization (CBC) method.³⁴ In CBC analysis, each molecule is assigned a value
8 between -1 and 1. CBC values of zero indicate a homogeneous distribution of molecules
9 and positive values indicate increasing localization of the two sets of molecules. The shift
10 in the CBC curve to predominantly positive values upon platelet stimulation, therefore,
11 indicates increased colocalization (Figure 1E). In non-stimulated platelets, approximately
12 20% of the Cx62 population co-localized with integrin β 3, which increased to
13 approximately 85% upon platelet activation (5 minutes) (Figure 1E).

14 To further explore the subcellular-location of Cx62 in platelets, we performed a linear
15 sucrose density gradient centrifugation on platelet homogenates, following nitrogen
16 cavitation. Cx62 was highly concentrated in the low-density fractions (1 and 2) with a
17 distribution profile similar to that of calreticulin [a marker of the dense tubular system
18 (DTS)] and β 3 integrin but was absent from higher density fractions (9 and 10), where α -
19 granule cargo such as TSP-1 was present (Supplemental figure 1B). These data are
20 consistent with the presence of Cx62 inside and on the surface of platelets, and further
21 recruitment to the cell surface during platelet activation.

22 **Cx62 Structural Prediction**

23 To assist in the design and analysis of an inhibitory mimetic peptide that specifically
24 targets Cx62(57), the monomeric and oligomeric structures of Cx62 were predicted. The

1 predicted tertiary structure of Cx62 from the IntFOLD server³⁵ reveals a protomer
2 (monomer subunit) consisting of four transmembrane helices, two extracellular loops, a
3 small bended N-terminal helix, and a long disordered cytoplasmic C-terminus loop
4 (Figure 2A-B). The ModFOLD6³⁶ global 3D model quality score for the full-length protein
5 was calculated as 0.43 ($p < 0.01$; less than a 1 in 100 chance of being incorrect), which
6 increased to 0.57 ($p < 0.001$; less than a 1 in 1000 chance of being incorrect) when the
7 long-disordered C-terminal loop was excluded. The calculated local (or per-residue)
8 errors indicate that the ordered regions of the Cx62 structure were modelled with high
9 confidence (Figure 2A). The tertiary structure model of Cx62 was subsequently used as a
10 target for *in silico* docking with the designed mimetic peptide, and for quaternary
11 structure assembly of the docked hemichannel complex (Figure 2C-E).

12 **Design of the Cx62 Mimetic Peptide (⁶²Gap27) and Protein-Ligand Docking Studies**

13 Due to the lack of an existing Cx62 selective inhibitor, we designed a mimetic peptide
14 (⁶²Gap27) that targets the second external loop of Cx62(57). To confirm the molecular
15 interactions between Cx62 and ⁶²Gap27, single ligand docking prediction was performed
16 using SwissDock. Six of the clusters from SwissDock contained alternative ligand poses
17 that were bound in approximately the same location at the end of the second external
18 loop (Figure 2B) (Supplemental figure 1D).

19 **Cx62 Forms Hemichannels and Gap Junctions in Platelets**

20 The exact mode of action by which different Gap27 peptides function is not clearly
21 understood. It is believed that they induce a conformational change in the hemichannel,
22 that prevents them from docking to form a gap junction and thus modulate the
23 permeability of the pore.^{21,26,37,38} To investigate this, we performed flow cytometry using
24 calcein-loaded human platelets, where efflux of calcein from the platelet cytosol was

1 measured to determine the effect of ⁶²Gap27 on Cx62 permeability (Figure 2F-G). Upon
2 thrombin stimulation (0.1 U/ml), calcein-associated fluorescence decreased in scrambled
3 peptide-treated cells by approximately 50%, indicating a release of dye. The treatment of
4 platelets with ⁶²Gap27 (100 µg/ml) prevented this loss of fluorescence. Since flow
5 cytometry-based analyses involve the gating of individual platelets, this indicates a role
6 for Cx62 hemichannels in regulating platelet permeability. Given the strong reduction in
7 the level of calcein efflux observed in ⁶²Gap27-treated platelets, it is plausible that the
8 peptide not only blocks Cx62 function but also inhibits the function of heteromers formed
9 by Cx62 with other connexin isoforms present on platelets (e.g. Cx37 and Cx40). At the
10 same thrombin concentration, ⁶²Gap27 did not reduce the extent of P-selectin exposure
11 (a marker of α-granule secretion) on the platelet surface, in comparison to scrambled
12 peptide treatment (Supplemental figure 1C). This suggests that the effects of ⁶²Gap27
13 observed on the permeability of hemichannels were not due to a reduction in the
14 activation state of platelets under these experimental conditions.

15 To evaluate the ability of ⁶²Gap27 to modulate gap junction-mediated intercellular
16 communication, fluorescence recovery after photobleaching (FRAP) analysis was
17 performed. Calcein-labeled platelets were incubated on coverslips coated with fibrinogen
18 and collagen together (to ensure maximal platelet adhesion and spreading) and a defined
19 region of cells was bleached by laser-exposure. Fluorescence recovery in ⁶²Gap27-treated
20 platelet aggregates was halved in comparison to scrambled peptide-treated samples
21 (17%) (Figure 2H-I). These findings demonstrate gap junction-mediated intercellular
22 communication between platelets and the inhibitory effect of ⁶²Gap27 on this.

23 The model of the Cx62 hemichannel complex (Figure 2C-D) revealed the two interacting
24 hemichannels forming the putative structure of the Cx62 gap junction channel (Figure

1 2E). In the close-up view of the interface, the residues mediating the inter-hemichannel
2 interactions are shown to be present in the first and second external loops (Figure 2E).
3 Protomer-inhibitor (Cx62-⁶²Gap27) interface residues were not found to coincide with
4 the interface residues of the 12-mer (docked-hemichannel). Additionally, there are no
5 SwissDock poses within the most common ⁶²Gap27 inhibitor interaction location (Figure
6 2D) that share any interface residues with the with 6-mer (hemichannel) assembly
7 (Figure 2D). Therefore, the inhibitor binding at this site is unlikely to disrupt either the
8 assembly of the 6-mer or the hemichannel-hemichannel complex (12-mer) (Figure 2E).
9 The predicted ⁶²Gap27 binding site was shown to coincide with the subsequent residues
10 from which the inhibitor was designed from (203-213, SRPTEKTIFML) (Figure 2B-C).
11 Specifically, the inhibitor is likely to bind to both T209 and L213 (bold circles Figure 2B).
12 The additional interaction of the inhibitor with residues in the loop regions from 180-183
13 (GFQM) suggests a potential mechanism for the regulation of flow through the pore. The
14 interaction may act to decrease the flexibility in the loop regions of the hemichannel pore,
15 thereby regulating permeability (Figure 2C-D).

16 **⁶²Gap27 Negatively Regulates Platelet Aggregation and Integrin Activation**

17 Light transmission aggregometry was used to investigate the effects of ⁶²Gap27 on human
18 washed platelets stimulated with a range of platelet activators that target different
19 receptors. The concentrations of platelet agonists used were optimized for each donor to
20 attain 50% maximal aggregation (EC₅₀) following 3 minutes of stimulation. Pre-treatment
21 of platelets with ⁶²Gap27 (50 and 100 µg/ml) for 5 minutes caused a concentration-
22 dependent inhibition to both CRP-XL (GPVI receptor-specific platelet agonist; EC₅₀: 0.2 -
23 0.4 µg/ml) and thrombin (EC₅₀: 0.05 - 0.08 U/ml) mediated platelet aggregation (Figure
24 3A-B). The scrambled peptide (100 µg/ml) was without effect (Supplemental figure 2A).

1 Inhibition of approximately 45% (50 µg/ml ⁶²Gap27) and 65% (100 µg/ml ⁶²Gap27) was
2 observed against CRP-XL and thrombin-stimulated aggregation respectively. ⁶²Gap27
3 also attenuated platelet aggregation stimulated by U46619 (EC₅₀: 0.25 - 0.4 µM)
4 (Supplemental figure 2B) and ADP (EC₅₀: 5-10 µM) (Supplemental figure 2C). These data
5 suggest that the effects of ⁶²Gap27 and therefore Cx62 functions are common to a variety
6 of platelet agonists.

7 Flow cytometry was used to measure the level of fibrinogen binding to activated integrin
8 αIIbβ3. Consistent with reduced aggregation, CRP-XL or thrombin-stimulated fibrinogen
9 binding was reduced by 55% and 65% respectively, following ⁶²Gap27 (100 µg/ml)
10 treatment (Figure 3C). The scrambled peptide was without effect (Supplemental figure
11 2D). Since fibrinogen binding was measured on gated single platelets, this provides
12 additional evidence that Cx62 hemichannels participate in the initiation of platelet
13 activation.

14 **The actions of ⁶²Gap27 are mediated selectively via Cx62**

15 To confirm the selectivity of ⁶²Gap27 mimetic peptide towards Cx62(57), its effects were
16 examined in Cx57^{-/-} platelets. The deletion of Cx57 did not alter the expression of other
17 platelet connexins such as Cx37 and Cx40 (Supplemental figure 3A-B). Similarly, the
18 deletion of Cx37 and Cx40 did not affect the expression of Cx57 (Supplemental figure 3C-
19 D). The expression of GPVI, integrin α2β1, integrin αIIbβ3 and GPIb on the surface of
20 Cx57^{+/+} and Cx57^{-/-} platelets was not significantly different (Supplemental figure 3E-H).

21 In comparison with scrambled peptide, treatment with ⁶²Gap27 (100 µg/ml) inhibited
22 CRP-XL-mediated fibrinogen binding in Cx57^{+/+} platelets (in PRP) but was without effect
23 on Cx57^{-/-} platelets (Figure 3D), confirming the specificity of ⁶²Gap27 for Cx57, which in
24 turn signifies its selectivity for Cx62 in humans. Additionally, ^{37,43}Gap27 and ⁴⁰Gap27

1 treatment (mimetic peptides for Cx37 and Cx40, respectively) significantly inhibited
2 fibrinogen binding in both Cx57^{+/+} and Cx57^{-/-} platelets (Figure 3D). Consistent with this,
3 ⁶²Gap27 also inhibited CRP-XL-stimulated fibrinogen binding in Cx37^{-/-} and Cx40^{-/-}
4 platelets to a similar extent as in littermate Cx37^{+/+} and Cx40^{+/+} platelets (Supplemental
5 Figure 4A-B). This suggests that Cx37, Cx40 and Cx57 hemichannels can function
6 independently of each other in platelets and the deletion of one connexin does not affect
7 the functions of other platelet connexins. Furthermore, a significant reduction in
8 fibrinogen binding was observed in CRP-XL-stimulated Cx57^{-/-} platelets, in comparison to
9 Cx57^{+/+} platelets. This indicates a fundamental role of Cx57 in regulating platelet
10 activation (Figure 3E).

11 **⁶²Gap27 Inhibits Platelet Secretion**

12 To assess the effects of ⁶²Gap27 on platelet secretion, P-selectin surface exposure and ATP
13 release (a marker of dense granule secretion) were evaluated using flow cytometry and
14 luciferin-luciferase luminescence assay, respectively. Incubation of platelets (in PRP)
15 with ⁶²Gap27 attenuated (in comparison to scrambled peptide) P-selectin exposure,
16 reaching 60% inhibition (at 100 µg/ml ⁶²Gap27) upon stimulation with CRP-XL or
17 thrombin (Figure 3F). Scrambled peptide (100 µg/ml) was without effect (Supplemental
18 Figure 4C). CRP-XL or thrombin-stimulated ATP release was also attenuated by
19 approximately 65% and 50% respectively upon treatment with ⁶²Gap27 (100 µg/ml), in
20 comparison to the scrambled peptide (Figure 3G).

21 Activated platelets synthesize TxA₂ to provide positive feedback, enabling the
22 recruitment of more platelets to the hemostatic plug.³⁹ Treatment of washed platelets
23 with ⁶²Gap27 attenuated both CRP-XL or thrombin stimulated production of TxB₂ (a
24 stable metabolite of TxA₂) (Figure 3H).

1 **Integrin-mediated platelet adhesion and signaling is regulated by Cx62**

2 Binding of fibrinogen to integrin α IIb β 3 initiates integrin clustering and outside-in
3 signaling that reinforces platelet activation and ensures the stability of thrombus.⁴⁰
4 Platelet spreading and clot-retraction are direct outcomes of outside-in signaling.⁴¹ The
5 effects of ⁶²Gap27 on platelet adhesion and spreading on fibrinogen coated-coverslips
6 were investigated. In comparison with the scrambled peptide-treated controls, ⁶²Gap27
7 (50 and 100 μ g/ml) significantly reduced platelet adhesion to fibrinogen (Figure 4A). The
8 proportion of adhered platelets reaching lamellipodia stage was also down-regulated by
9 ⁶²Gap27 (Figure 4A). In the absence of agonist pre-stimulation, the ability of ⁶²Gap27 to
10 attenuate platelet adhesion to fibrinogen-coated coverslips suggests underlying levels of
11 platelet signaling that are associated with Cx62 function and can modulate integrin
12 affinity and fibrinogen binding. Consistent with this, fibrin clot retraction was also
13 inhibited, indicating the role of Cx62 in the formation and consolidation of thrombi
14 (Figure 4B).

15 **Cx62(57) Modulates Thrombosis and Haemostasis**

16 To elucidate the function of Cx62 in platelets under shear in whole blood, we determined
17 the effects of ⁶²Gap27 on thrombus formation *in vitro* using fluorescence microscopy.
18 DiOC₆-labelled whole human blood, treated with scrambled peptide or ⁶²Gap27
19 (100 μ g/ml), was perfused through collagen-coated microfluidic flow channels for 10
20 minutes at a shear rate of 500 s⁻¹ (20 dyn/cm²). The mean fluorescence intensity of
21 thrombi in ⁶²Gap27-treated whole-blood was reduced by 70%, in comparison with
22 scrambled peptide (Figure 4C). Furthermore, the extent of thrombus surface coverage
23 was also attenuated in ⁶²Gap27-treated samples, consistent with impaired adhesion of
24 platelets (Supplemental Figure 4D).

1 The acute effects of ⁶²Gap27 (100 µg/ml) on thrombosis was investigated in mice
2 following laser-induced injury of cremaster muscle arterioles and observed using
3 intravital microscopy. Large and stable thrombi were formed in scrambled peptide-
4 treated mice, whereas, ⁶²Gap27 treatment resulted in the development of substantially
5 smaller thrombi that were unstable and embolized, resulting in a three-fold reduction in
6 the mean of maximum fluorescence intensity (Figure 4D-E).

7 The contribution of Cx57(62) to haemostasis was assessed by measuring tail-bleeding
8 time. While bleeding stopped in all 9 scrambled peptide-treated mice (mean bleeding
9 time, 459 ± 81 seconds), the time to cessation of bleeding was dramatically increased in
10 ⁶²Gap27-treated mice where 7 of 10 mice bled for more than 20 minutes (Figure 4F). In
11 alignment with this, the amount of blood loss in ⁶²Gap27-treated mice was higher than
12 the scrambled peptide-treated mice, indicating impaired hemostasis (Figure 4G).

13 **⁶²Gap27 negatively regulates GPVI and thrombin-mediated signaling in platelets**

14 Given the effects of ⁶²Gap27 on CRP-XL-mediated platelet responses and thrombus
15 formation *in vitro* and *in vivo*, we investigated the effects of ⁶²Gap27 on signal
16 transduction stimulated by the GPVI receptor. Pre-treatment of platelets (non-
17 aggregation conditions) with ⁶²Gap27 (50 and 100 µg/mL) for 5 minutes reduced CRP-
18 XL-stimulated total protein tyrosine phosphorylation by approximately 25% and 30%
19 respectively, in comparison with scrambled peptide (Figure 5A). Consistent with this, 100
20 µg/ml of ⁶²Gap27 inhibited the tyrosine phosphorylation of Syk (Tyr^{525/526}) by ~30%
21 (Figure 5B). This indicated that ⁶²Gap27 inhibits the early stages of the GPVI signaling.
22 Activated Syk results in phosphorylation of the transmembrane adapter protein LAT,
23 followed with PLCγ2 phosphorylation.⁴¹ Tyrosine phosphorylation of LAT (Tyr²⁰⁰) and

1 PLC γ 2 (Tyr¹²¹⁷) were observed to be diminished by 40% and 25% respectively, following
2 ⁶²Gap27 treatment (100 μ g/ml) compared to the scrambled peptide (Figure 5C-D).

3 Downstream of PLC γ 2, ⁶²Gap27 inhibited CRP-XL-stimulated (0.25 μ g/ml) calcium
4 mobilization by 45%, when compared with scrambled peptide (Figure 5E). Treatment
5 with saturating concentrations of EGTA (2 mM) to prevent Ca²⁺ influx, in the presence of
6 scrambled peptide, reduced CRP-XL-mediated rise in cytosolic calcium concentration by
7 approximately 50%, in comparison to scrambled peptide alone. The inhibitory effects of
8 ⁶²Gap27 (100 μ g/ml) were found to be additive to the reduction caused by EGTA-
9 scrambled peptide, following stimulation with CRP-XL (0.5 μ g/ml) (Supplemental figure
10 5A), suggesting that Cx62 can modulate the release of calcium from intracellular stores.
11 Consistent with this, CRP-XL evoked PKC substrate phosphorylation was also found to be
12 attenuated by 45% (Figure 5F), following incubation with ⁶²Gap27 (100 μ g/ml).
13 Furthermore, ⁶²Gap27 also reduced ERK1/2 phosphorylation in CRP-XL stimulated
14 platelets, which is consistent with the down-regulation of CRP-XL evoked TxA₂ (TxB₂)
15 release (Supplemental Figure 5F). Similar inhibition was observed following ^{37,43}Gap27
16 treatment (Supplemental Figure 5F).

17 In comparison with scrambled peptide, ⁶²Gap27 also inhibited thrombin-evoked total
18 protein tyrosine phosphorylation, calcium mobilization, the release of calcium from
19 intracellular stores, PKC substrate phosphorylation and ERK1/2 phosphorylation
20 (Supplemental Figure 5B-F).

21 To confirm that signaling events following GPVI activation were affected by Cx57 in mice,
22 GPVI signaling events were investigated in Cx57^{+/+} and Cx57^{-/-} platelets. Cx57-deficient
23 platelets showed reduced CRP-XL-evoked total tyrosine phosphorylation and
24 phosphorylation of Syk (Tyr^{525/526}), LAT (Tyr²⁰⁰), PLC γ 2 (Tyr¹²¹⁷) and PKC substrates in

1 comparison with Cx57^{+/+} mouse platelets (Figure 6A-E), suggesting the importance of
2 Cx57 in GPVI signaling.

3 **⁶²Gap27 activates PKA independently of cyclic nucleotide signaling**

4 The effects of ⁶²Gap27 on GPVI-specific signaling events were surprising given the ability
5 of the peptide to inhibit platelet responses to several agonists including thrombin, which
6 would suggest a mechanism that would be common to each. Platelets are maintained in a
7 quiescent state by prostaglandin I₂ (PGI₂) and nitric oxide (NO), released by endothelial
8 cells.^{42,43} PGI₂ binds to IP receptor and stimulates the production of cyclic adenosine
9 monophosphate (cAMP), while NO stimulates the production of cyclic guanosine
10 monophosphate (cGMP) which activate protein kinase A (PKA) and protein kinase G
11 (PKG), respectively, and inhibit platelet activation through phosphorylation of multiple
12 substrates.^{44,45}

13 We therefore explored the effect of ⁶²Gap27 on PKA and PKG-dependent signaling in
14 platelets by measuring the extent of VASP (Vasodilator-stimulated phosphoprotein)
15 phosphorylation at Ser¹⁵⁷ and Ser²³⁹ respectively (PKA- and PKG-selective
16 phosphorylation sites). The treatment of resting platelets with ⁶²Gap27 upregulated the
17 phosphorylation of VASP S¹⁵⁷ in comparison with scrambled peptide (Figure 7A), while
18 no effect on VASP S²³⁹ was observed (Supplemental figure 6A). VASP S¹⁵⁷ phosphorylation
19 was also elevated in CRP-XL-stimulated platelets that were treated with ⁶²Gap27 in
20 comparison with scrambled peptide-treated control (Figure 7B). Additionally, we
21 observed that resting platelets when treated with ^{37,43}Gap27 also upregulate VASP S¹⁵⁷
22 phosphorylation in comparison with scrambled peptide (Supplemental figure 6B). This
23 suggests that activation of PKA represents a general mechanism by which Gap27 peptides
24 inhibit platelet functions.

1 VASP phosphorylation was reversed following treatment with PKA inhibitors; H89 (10
2 μM) (Figure 7C) or PKI (10 μM) (Figure 7D), confirming a key role for PKA in this process.
3 We examined cAMP concentration in resting and CRP-XL activated platelets treated with
4 $^{62}\text{Gap27}$ (100 $\mu\text{g}/\text{ml}$) or scrambled peptide. Treatment with $^{62}\text{Gap27}$ did not elevate cAMP
5 levels in resting or CRP-XL-stimulated platelets (Figure 7E). Similarly, $^{62}\text{Gap27}$ did not up-
6 regulate cAMP concentration in thrombin-stimulated platelets (Supplemental figure 6C).
7 In agreement with this, $^{62}\text{Gap27}$ -stimulated VASP phosphorylation was not reduced by
8 treatment with, Rp-8-CPT-cAMPs (200 μM) (Figure 7F), a competitive inhibitor of cAMP-
9 binding to PKA or the adenylyl cyclase inhibitor SQ22536 (100 μM) (Figure 7G). Together
10 these data indicate that $^{62}\text{Gap27}$ inhibits platelet function through activation of PKA,
11 independently of cAMP.

12 S^{157} VASP phosphorylation was also investigated in $\text{Cx57}^{+/+}$ and $\text{Cx57}^{-/-}$ mouse platelets
13 in the presence and absence of PKA inhibitors. Consistent with observations on human
14 platelets, $^{62}\text{Gap27}$ -treated $\text{Cx57}^{+/+}$ mouse platelets exhibited enhanced VASP S^{157}
15 phosphorylation, in comparison to scrambled peptide-treated samples, which was
16 reversed upon treatment with the PKA inhibitor H89 (Figure 7H) but not reversed by Rp-
17 8-CPT-cAMPs (Figure 7I). $^{62}\text{Gap27}$ treatment of $\text{Cx57}^{-/-}$ mouse platelets did not result in
18 VASP phosphorylation, further confirming the specificity of action of $^{62}\text{Gap27}$ (Figure 7H,
19 7J).

20 It has been reported that PKC isoforms, PI3-Kinase or PKB/Akt can contribute towards
21 the phosphorylation of VASP.^{32,46,47} However, $^{62}\text{Gap27}$ induced VASP phosphorylation in
22 platelets was not prevented upon treatment with either a pan-PKC inhibitor GF109203X
23 (10 μM), PI3-Kinase inhibitor LY29400 (100 μM) or AKT inhibitor IV (5 μM)
24 (Supplemental figure 6D-F). Together, these observations provide insight into the

1 mechanism through which the actions of ⁶²Gap27 on Cx62 inhibit platelet activation
2 through the up-regulation of PKA activity independently of cAMP.

3 **Discussion**

4 Growing evidence suggests the role of different platelet surface receptors (Eph kinase,
5 CD72, plexin-B1 and CD40L) in contact-dependent signaling that is required for the
6 formation of a stable thrombus.^{48,49} The contributions of gap junction-mediated
7 intercellular communication to platelet function and thrombus growth represents a
8 recently discovered paradigm for the regulation of circulating cells following cell-cell
9 contact. In this study, we describe the presence of Cx62(57) in platelets, which was found
10 in a punctate arrangement in the cytosol and translocated to the plasma membrane upon
11 activation. These observations are consistent with the formation of hemichannels on the
12 cell membrane, and the formation of gap junctions as adjacent platelets make sustained
13 contact within a thrombus. The mechanism by which Cx62 traffics to the cell membrane
14 upon platelet activation remains to be established. In other cell types, connexins
15 translocate to the plasma membrane through the classical secretory pathway.⁵⁰⁻⁵⁴ In
16 platelets, Cx62 is distributed similarly to calreticulin, present within the DTS (remnants
17 of megakaryocyte smooth endoplasmic reticulum) but not in subcellular fractions that
18 contain α -granule cargo or cytosolic proteins, suggesting a non-classical secretion
19 mechanism. It has been proposed that connexins are chaperoned by protein disulfide-
20 isomerases, as connexin extracellular loops are exposed in the endoplasmic reticulum to
21 form disulfide bonds.⁵⁵ Protein disulfide-isomerases also localize to the platelet DTS and
22 become mobilized in activated platelets, and therefore may share mechanisms of
23 trafficking towards the cell surface with Cx62.⁵⁶

1 To determine the role of Cx62 in the regulation of platelet function, a novel synthetic
2 mimetic peptide (⁶²Gap27) targeting Cx62(57) was designed. Its inability to inhibit CRP-
3 XL-mediated fibrinogen binding in Cx57^{-/-} mice, in comparison to Cx57^{+/+} confirmed its
4 selective action towards Cx57/62. Incubation with ⁶²Gap27 significantly down-regulated
5 calcein release from activated platelets in suspension (non-aggregated), which points
6 towards a role for connexin hemichannels in the early phases of platelet activation. This
7 was associated with diminished markers of platelet activation such as fibrinogen binding,
8 and dense- (ATP-release) and α -granule (P-selectin exposure) secretion. It is interesting
9 to note that pannexin-1 releases cytosolic ATP, which primes platelet responses when
10 exposed to low agonist concentrations via the effect of the ATP on P2X1 channels.⁵⁷ The
11 possibility that direct release of ATP represents a mechanism through which connexins
12 contribute to platelet activation is a priority for investigation in future work. Additionally,
13 FRAP experiments confirmed the formation of Cx62-containing gap junctions between
14 adjacent platelets. Thrombus stability was suppressed both *in vitro* and *in vivo* following
15 treatment with ⁶²Gap27, indicating the vital role of gap junction intercellular
16 communication in the reinforcement of thrombi. It is plausible that such robust effects of
17 ⁶²Gap27 on thrombosis *in vivo* are partly due to its effects on other circulating or
18 endothelial cells. Further work to explore this will require transgenic mice with platelet-
19 specific deletion of Cx57.

20 Studies in Cx57-deficient mouse platelets identified that Cx57(62) positively regulates
21 platelet function, hemostasis and thrombus formation. These functions are shared with
22 Cx37 and Cx40, the other principal platelet connexins.^{21,26,27,58} We also observed negative
23 regulation of Ca²⁺ mobilization following treatment with ⁶²Gap27. This inhibition was
24 identified to be partly due to reduced Ca²⁺ mobilization from stores, although effects on

1 the Ca²⁺ influx cannot be ruled out. Numerous channels regulate calcium mobilization in
2 platelets, including P2X1, TRPC6, STIM1 and Orai1.^{41,42,59} Notably Cx43 has been shown
3 to interact with the calcium channel P2X1.⁶⁰ It is therefore possible that Cx62 may
4 associate with a platelet calcium channel to influence calcium mobilization.

5 PKA activation plays an essential role in the regulation of platelet function by controlling
6 several aspects of activation including integrin α IIb β 3 affinity, inositol 1,4,5-
7 trisphosphate (IP₃) receptor function and shape change via actin polymerisation.^{61,62}

8 While cAMP is a key activator of PKA in platelets, studies have also reported that PKA
9 activity can be stimulated by collagen or thrombin in a cAMP-independent manner, and
10 in other cells, cAMP-independent PKA activation has been attributed to the effects of
11 sphingosine and free radicals.^{47,63-65} We provide compelling evidence that the inhibitory
12 effects of ⁶²Gap27 on platelets are mediated through increased PKA activity,
13 independently of cAMP. Notably, cAMP-independent upregulation of PKA signalling
14 occurs in unstimulated platelets which suggest a direct influence of ⁶²Gap27 binding to
15 Cx62 on PKA activity. The mechanism by which ⁶²Gap27 induces PKA activation remains
16 unclear. Since ⁶²Gap27 is predicted to primarily induce conformational changes in Cx62
17 (Figure 2C and Supplemental figure 1D), we speculate that ⁶²Gap27 binding may influence
18 the ability of PKA to interact with the connexin, or localized A-kinase anchoring proteins
19 (AKAPs) that may modulate PKA activity in the vicinity of the connexin. The lack of
20 increased VASP phosphorylation in Cx57-deficient platelets in the absence of ⁶²Gap27
21 suggests that Cx binding of PKA may result in its activation, while non-Cx57-bound PKA
22 is inactive.

23 It is possible that connexin-associated PKA may be responsible for the regulation of
24 connexin trafficking (noting that platelet activation results in recruitment to the plasma

1 membrane) or regulation of channel function. Further work will be required to determine
2 the precise mechanism of PKA activation in the presence or absence of ⁶²Gap27 to assess
3 whether this represents conformational perturbation of Cx62 by the peptide or involves
4 PKA-mediated phosphorylation of the connexin that modulates channel activity. Notably
5 the absence of Cx57, which in itself does not alter PKA-dependent signalling in
6 unstimulated platelets, results in diminished levels of platelet activation. This supports a
7 role for Cx57 channel activity in the function of platelets. It remains to be established
8 whether the inhibitory effects of ⁶²Gap27 are solely mediated through stimulation of PKA
9 signalling (which is dependent on the presence of the connexin) or also through
10 modulation of channel function. It is pertinent that several studies indicate the
11 involvement of PKA and PKG in regulating the phosphorylation of Cx32, Cx35/36, Cx40,
12 Cx43 and Cx50 in various cell types.⁶⁶⁻⁷¹ In the absence of antibodies that allow the
13 immunoprecipitation of Cx62, we have, thus far, been unable to determine whether Cx62
14 represents a PKA substrate in platelets.

15 The potential link between Cx62 and thrombotic disease risk is uncertain, and relevant
16 mutations that might modulate such risk have not been identified. The expression of Cx62
17 is not widespread which may enhance its potential as a therapeutic target, minimising
18 side-effects, noting that systemic genetic deletion of Cx57 in mice is well-tolerated. Our
19 Gap27 peptide docking experiments are suggestive of regulation of gating by
20 conformational changes, although, as discussed, modulation of PKA-dependent signaling
21 may also be important. Non-peptide based selective inhibitors would need to be
22 developed that potentially mimic peptide binding and/or associated conformational
23 changes in order to develop this further. A suggested starting point for such work would

1 be the development of biologics that target the proposed ⁶²Gap27 binding sequences
2 predicted in Cx62.

3 In summary, we have identified key functions for the orphan connexin, Cx62(57) in
4 platelets in the regulation of hemostasis and thrombosis. We have revealed a new
5 signaling mechanism through which Cx62(57) and its inhibitor modulate cellular function
6 and highlight the importance of connexin hemichannels and gap junctions in the
7 regulation of the function of circulating cells.

8 **Acknowledgments**

9 This work was supported by the Saudi Cultural Bureau (London), a Felix Scholarship
10 (2014-17), grants from the British Heart Foundation (RG/09/011/28094 and
11 RG/15/2/31224), the Medical Research Council (MR/J002666/1 and MR/P023878/1),
12 and the Biotechnology and Biological Sciences Research Council.

13 **Authorship**

14 K.A.S. and G.D.F. designed the research, performed experiments, analysed results, and
15 wrote the article. P.S., A.H.M., L.M.H., S.K.A and A.E. performed experiments and analysed
16 results. T.S., A.R.S., R.A., M.A., M.C., A.P.B., NK, SV, A.J.U and C.I.J performed experiments.
17 L.J.M. and J.M.G. designed the research, analysed data and wrote the article.

18 **Footnotes**

19 *KAS and GDF are joint first authors.

20 **Conflict-of-interest disclosure:** The authors declare no competing financial interests.

21 **References**

22 1. Batra N, Kar R, Jiang JX. Gap Junctions and Hemichannels in Signal Transmission, Function and
23 Development of Bone. *Biochimica et biophysica acta*. 2012;1818(8):1909-1918.

- 1 2. Goodenough DA, Paul DL. Gap junctions. *Cold Spring Harb Perspect Biol.* 2009;1(1):a002576.
- 2 3. Hanner F, Sorensen CM, Holstein-Rathlou N-H, Peti-Peterdi J. Connexins and the kidney. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.*
- 3 2010;298(5):R1143-R1155.
- 4 4. Koval M, Molina SA, Burt JM. Mix and match: investigating heteromeric and heterotypic gap
- 5 junction channels in model systems and native tissues. *FEBS letters.* 2014;588(8):1193-1204.
- 6 5. Huettner JE, Lu A, Qu Y, Wu Y, Kim M, McDonald JW. Gap junctions and connexon
- 7 hemichannels in human embryonic stem cells. *Stem Cells.* 2006;24(7):1654-1667.
- 8 6. Kostin S, Dammer S, Hein S, Klovekorn WP, Bauer EP, Schaper J. Connexin 43 expression and
- 9 distribution in compensated and decompensated cardiac hypertrophy in patients with aortic
- 10 stenosis. *Cardiovasc Res.* 2004;62(2):426-436.
- 11 7. Darrow BJ, Fast VG, Kléber AG, Beyer EC, Saffitz JE. Functional and structural assessment of
- 12 intercellular communication. Increased conduction velocity and enhanced connexin
- 13 expression in dibutyryl cAMP-treated cultured cardiac myocytes. *Circ Res.* 1996;79(2):174-
- 14 183.
- 15 8. Oyamada M, Kimura H, Oyamada Y, Miyamoto A, Ohshika H, Mori M. The expression,
- 16 phosphorylation, and localization of connexin 43 and gap-junctional intercellular
- 17 communication during the establishment of a synchronized contraction of cultured neonatal
- 18 rat cardiac myocytes. *Exp Cell Res.* 1994;212(2):351-358.
- 19 9. Molica F, Figueroa XF, Kwak BR, Isakson BE, Gibbins JM. Connexins and Pannexins in Vascular
- 20 Function and Disease. *Int J Mol Sci.* 2018;19(6).
- 21 10. Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function.
- 22 *Physiology (Bethesda).* 2004;19:277-284.
- 23 11. Billaud M, Lohman AW, Johnstone SR, Biwer LA, Mutchler S, Isakson BE. Regulation of cellular
- 24 communication by signaling microdomains in the blood vessel wall. *Pharmacological reviews.*
- 25 2014;66(2):513-569.
- 26 12. Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of vascular connexin
- 27 expression in atherosclerotic plaques. *Arterioscler Thromb Vasc Biol.* 2002;22(2):225-230.
- 28 13. Johnstone SR, Ross J, Rizzo MJ, et al. Oxidized phospholipid species promote in vivo
- 29 differential cx43 phosphorylation and vascular smooth muscle cell proliferation. *The*
- 30 *American journal of pathology.* 2009;175(2):916-924.
- 31 14. Yeh HI, Lu CS, Wu YJ, et al. Reduced expression of endothelial connexin37 and connexin40 in
- 32 hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment. *Arterioscler*
- 33 *Thromb Vasc Biol.* 2003;23(8):1391-1397.
- 34 15. Ilhan F, Kalkanli ST. Atherosclerosis and the role of immune cells. *World journal of clinical*
- 35 *cases.* 2015;3(4):345-352.
- 36 16. Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human
- 37 atherosclerosis and atherothrombosis. *Clinical and experimental immunology.*
- 38 2015;179(2):173-187.
- 39 17. Hartwig H, Silvestre Roig C, Daemen M, Lutgens E, Soehnlein O. Neutrophils in atherosclerosis.
- 40 A brief overview. *Hamostaseologie.* 2015;35(2):121-127.
- 41 18. Anand RJ, Dai S, Gripar SC, et al. A role for connexin43 in macrophage phagocytosis and host
- 42 survival after bacterial peritoneal infection. *J Immunol.* 2008;181(12):8534-8543.
- 43 19. Sarieddine MZ, Scheckenbach KE, Foglia B, et al. Connexin43 modulates neutrophil
- 44 recruitment to the lung. *J Cell Mol Med.* 2009;13(11-12):4560-4570.
- 45 20. Machtaler S, Dang-Lawson M, Choi K, Jang C, Naus CC, Matsuuchi L. The gap junction protein
- 46 Cx43 regulates B-lymphocyte spreading and adhesion. *Journal of cell science.*
- 47 2011;124(15):2611-2621.
- 48 21. Vaiyapuri S, Flora GD, Gibbins JM. Gap junctions and connexin hemichannels in the regulation
- 49 of haemostasis and thrombosis. *Biochem Soc Trans.* 2015;43(3):489-494.
- 50 22. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic
- 51 heart disease. *European Heart Journal: Acute Cardiovascular Care.* 2012;1(1):60-74.
- 52 23. Flora GD, Nayak MK. A Brief Review of Cardiovascular Diseases, Associated Risk Factors and
- 53 Current Treatment Regimes. *Curr Pharm Des.* 2019;25(38):4063-4084.
- 54

- 1 24. Vaiyapuri S, Sage T, Rana RH, et al. EphB2 regulates contact-dependent and contact-
2 independent signaling to control platelet function. *Blood*. 2015;125(4):720-730.
- 3 25. Prevost N, Woulfe D, Tognolini M, Brass LF. Contact-dependent signaling during the late
4 events of platelet activation. *J Thromb Haemost*. 2003;1(7):1613-1627.
- 5 26. Vaiyapuri S, Jones CI, Sasikumar P, et al. Gap junctions and connexin hemichannels underpin
6 hemostasis and thrombosis. *Circulation*. 2012;125(20):2479-2491.
- 7 27. Vaiyapuri S, Moraes LA, Sage T, et al. Connexin40 regulates platelet function. *Nature*
8 *communications*. 2013;4:2564.
- 9 28. Sohl G, Joussem A, Kociok N, Willecke K. Expression of connexin genes in the human retina.
10 *BMC Ophthalmol*. 2010;10:27.
- 11 29. Morel S. Multiple roles of connexins in atherosclerosis- and restenosis-induced vascular
12 remodelling. *J Vasc Res*. 2014;51(2):149-161.
- 13 30. Vaiyapuri S, Roweth H, Ali MS, et al. Pharmacological actions of nobiletin in the modulation of
14 platelet function. *Br J Pharmacol*. 2015;172(16):4133-4145.
- 15 31. Flora GD, Sahli KA, Sasikumar P, et al. Non-genomic effects of the Pregnane X Receptor
16 negatively regulate platelet functions, thrombosis and haemostasis. *Sci Rep*. 2019;9(1):17210.
- 17 32. Unsworth AJ, Flora GD, Sasikumar P, et al. RXR Ligands Negatively Regulate Thrombosis and
18 Hemostasis. *Arterioscler Thromb Vasc Biol*. 2017;37(5):812-822.
- 19 33. Sáez JC, Retamal MA, Basilio D, Bukauskas FF, Bennett MV. Connexin-based gap junction
20 hemichannels: gating mechanisms. *Biochimica et Biophysica Acta (BBA)-Biomembranes*.
21 2005;1711(2):215-224.
- 22 34. Malkusch S, Endesfelder U, Mondry J, Gelleri M, Verveer PJ, Heilemann M. Coordinate-based
23 colocalization analysis of single-molecule localization microscopy data. *Histochem Cell Biol*.
24 2012;137(1):1-10.
- 25 35. McGuffin LJ, Atkins JD, Salehe BR, Shuid AN, Roche DB. IntFOLD: an integrated server for
26 modelling protein structures and functions from amino acid sequences. *Nucleic Acids Res*.
27 2015;43(W1):W169-173.
- 28 36. Maghrabi AHA, McGuffin LJ. ModFOLD6: an accurate web server for the global and local
29 quality estimation of 3D protein models. *Nucleic Acids Res*. 2017;45(W1):W416-w421.
- 30 37. Verselis VK, Srinivas M. Connexin channel modulators and their mechanisms of action.
31 *Neuropharmacology*. 2013;75:517-524.
- 32 38. Leybaert L, Braet K, Vandamme W, Cabooter L, Martin PE, Evans WH. Connexin channels,
33 connexin mimetic peptides and ATP release. *Cell Commun Adhes*. 2003;10(4-6):251-257.
- 34 39. Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the
35 use of aspirin with particular regard to dual anti-platelet therapy. *British journal of clinical*
36 *pharmacology*. 2011;72(4):619-633.
- 37 40. Durrant TN, van den Bosch MT, Hers I. Integrin α IIb β 3 outside-in signaling. *Blood*.
38 2017;130(14):1607-1619.
- 39 41. Li Z, Delaney MK, O'brien KA, Du X. Signaling during platelet adhesion and activation.
40 *Arteriosclerosis, thrombosis, and vascular biology*. 2010;30(12):2341-2349.
- 41 42. Procter NE, Hurst NL, Nooney VB, et al. New Developments in Platelet Cyclic Nucleotide
42 Signalling: Therapeutic Implications. *Cardiovascular drugs and therapy*. 2016;30(5):505-513.
- 43 43. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. *Journal of*
44 *Thrombosis and Haemostasis*. 2012;10(2):167-176.
- 45 44. Noé L, Peeters K, Izzi B, Van Geet C, Freson K. Regulators of platelet cAMP levels: clinical and
46 therapeutic implications. *Current medicinal chemistry*. 2010;17(26):2897-2905.
- 47 45. Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood
48 cells. cGMP: Generators, Effectors and Therapeutic Implications: Springer; 2009:533-548.
- 49 46. Gambaryan S, Kobsar A, Rukoyatkina N, et al. Thrombin and collagen induce a feedback
50 inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of PKA
51 from an NF- κ B-I κ B complex. *Journal of Biological Chemistry*. 2010:jbc. M109. 077602.
- 52 47. Unsworth A, Kriek N, Bye A, et al. PPAR γ agonists negatively regulate α II b β 3 integrin outside-
53 in signaling and platelet function through up-regulation of protein kinase A activity. *Journal*
54 *of Thrombosis and Haemostasis*. 2017;15(2):356-369.

- 1 48. Brass LF, Zhu L, Stalker TJ. Minding the gaps to promote thrombus growth and stability. *The*
2 *Journal of clinical investigation*. 2005;115(12):3385-3392.
- 3 49. Brass LF, Zhu L, Stalker TJ. Novel therapeutic targets at the platelet vascular interface.
4 *Arteriosclerosis, thrombosis, and vascular biology*. 2008;28(3):s43-s50.
- 5 50. Falk MM, Baker SM, Gumpert AM, Segretain D, Buckheit RW, 3rd. Gap junction turnover is
6 achieved by the internalization of small endocytic double-membrane vesicles. *Mol Biol Cell*.
7 2009;20(14):3342-3352.
- 8 51. Falk MM, Buehler LK, Kumar NM, Gilula NB. Cell-free synthesis and assembly of connexins into
9 functional gap junction membrane channels. *Embo j*. 1997;16(10):2703-2716.
- 10 52. Falk MM, Gilula NB. Connexin membrane protein biosynthesis is influenced by polypeptide
11 positioning within the translocon and signal peptidase access. *J Biol Chem*.
12 1998;273(14):7856-7864.
- 13 53. Falk MM, Kumar NM, Gilula NB. Membrane insertion of gap junction connexins: polytopic
14 channel forming membrane proteins. *J Cell Biol*. 1994;127(2):343-355.
- 15 54. Thomas T, Jordan K, Simek J, et al. Mechanisms of Cx43 and Cx26 transport to the plasma
16 membrane and gap junction regeneration. *J Cell Sci*. 2005;118(Pt 19):4451-4462.
- 17 55. John SA, Revel J-P. Connexon integrity is maintained by non-covalent bonds: Intramolecular
18 disulfide bonds link the extracellular domains in rat connexin-43. *Biochemical and Biophysical*
19 *Research Communications*. 1991;178(3):1312-1318.
- 20 56. Crescente M, Pluthero FG, Li L, et al. Intracellular Trafficking, Localization, and Mobilization
21 of Platelet-Borne Thiol Isomerases. *Arterioscler Thromb Vasc Biol*. 2016;36(6):1164-1173.
- 22 57. Taylor KA, Wright JR, Vial C, Evans RJ, Mahaut-Smith MP. Amplification of human platelet
23 activation by surface pannexin-1 channels. *J Thromb Haemost*. 2014;12(6):987-998.
- 24 58. Molica F, Stierlin FB, Fontana P, Kwak BR. Pannexin- and Connexin-Mediated Intercellular
25 Communication in Platelet Function. *Int J Mol Sci*. 2017;18(4).
- 26 59. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost*.
27 2009;7(7):1057-1066.
- 28 60. Jiang L, Bardini M, Keogh A, dos Remedios CG, Burnstock G. P2X1 receptors are closely
29 associated with connexin 43 in human ventricular myocardium. *Int J Cardiol*. 2005;98(2):291-
30 297.
- 31 61. Unsworth AJ, Kriek N, Bye AP, et al. PPAR γ agonists negatively regulate α IIb β 3 integrin
32 outside-in signaling and platelet function through up-regulation of protein kinase A activity.
33 *Journal of thrombosis and haemostasis : JTH*. 2017;15(2):356-369.
- 34 62. Beck F, Geiger J, Gambaryan S, et al. Time-resolved characterization of cAMP/PKA-dependent
35 signaling reveals that platelet inhibition is a concerted process involving multiple signaling
36 pathways. *Blood*. 2014;123(5):e1-e10.
- 37 63. Gambaryan S, Kobsar A, Rukoyatkin N, et al. Thrombin and collagen induce a feedback
38 inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of
39 protein kinase A from an NF κ B-I κ B complex. *J Biol Chem*. 2010;285(24):18352-
40 18363.
- 41 64. Ma Y, Pitson S, Hercus T, Murphy J, Lopez A, Woodcock J. Sphingosine activates protein kinase
42 A type II by a novel cAMP-independent mechanism. *Journal of Biological Chemistry*.
43 2005;280(28):26011-26017.
- 44 65. Kohr MJ, Traynham CJ, Roof SR, Davis JP, Ziolo MT. cAMP-independent activation of protein
45 kinase A by the peroxynitrite generator SIN-1 elicits positive inotropic effects in
46 cardiomyocytes. *J Mol Cell Cardiol*. 2010;48(4):645-648.
- 47 66. Lampe PD, Lau AF. The effects of connexin phosphorylation on gap junctional communication.
48 *Int J Biochem Cell Biol*. 2004;36(7):1171-1186.
- 49 67. Liu J, Vitorin JFE, Weintraub ST, et al. Phosphorylation of connexin 50 by protein kinase A
50 enhances gap junction and hemichannel function. *Journal of Biological Chemistry*. 2011;:jbc.
51 M111. 218735.
- 52 68. Ouyang X, Winbow VM, Patel LS, Burr GS, Mitchell CK, O'Brien J. Protein kinase A mediates
53 regulation of gap junctions containing connexin35 through a complex pathway. *Molecular*
54 *brain research*. 2005;135(1):1-11.

- 1 69. Pidoux G, Taskén K. Anchored PKA as a gatekeeper for gap junctions. *Communicative &*
2 *Integrative Biology*. 2015;8(4):e1057361.
- 3 70. van Rijen HV, van Veen TA, Hermans MM, Jongsma HJ. Human connexin40 gap junction
4 channels are modulated by cAMP. *Cardiovascular research*. 2000;45(4):941-951.
- 5 71. Wynn J, Shah U, Murray SA. Redistribution of connexin 43 by cAMP: a mechanism for growth
6 control in adrenal cells. *Endocr Res*. 2002;28(4):663-668.

7

8

1 **Figure Legends**

2 **Figure 1. Expression and localization of Cx62 in platelets (A)** The presence of Cx62
3 was examined by immunoblot analysis of whole-cell lysates from human and mouse
4 whole platelets, Meg01 and HeLa cells using a rabbit polyclonal anti-GJA10 antibody.
5 Actin was used as a loading control. **(B, C)** The Localisation of Cx62 in resting and
6 activated (with 5 μ M U46619 in the presence of 3 μ g/ml integrilin) permeabilized human
7 platelets (0.2% Triton-X-100) was investigated using immunofluorescence microscopy.
8 Cx62 (in red) and membrane GPIb receptors (in green) were stained using anti-GJA10
9 and anti-GPIb primary antibodies respectively. Visualization was performed using Alexa-
10 647 and Alexa-488-conjugated secondary antibodies respectively. **(D)** The distribution of
11 Cx62 was also studied using super-resolution STORM microscopy. Resting and activated
12 permeabilized human platelets were stained using anti-GJA10 and anti-integrin β_3
13 primary antibodies and visualized using Alexa-647 and Alexa-555-conjugated secondary
14 antibodies respectively. **(E)** Coordinate-based colocalization (CBC) analysis was
15 performed to determine the levels of Cx62 and β_3 integrin colocalization in resting (0, red
16 line) platelets and following stimulation with thrombin (1 U/mL) for 5 minutes (300, blue
17 line). A CBC value of zero represents a random distribution and a positive value indicates
18 closer distribution than expected at random. Data are representative of ≥ 3 separate
19 experiments.

20

21 **Figure 2. Design of the ⁶²Gap27 mimetic peptide and its role in the regulation of**
22 **intercellular communication. (A)** Predicted 3D model of the Cx62 tertiary structure.
23 The ribbon view of the structure is colored using the temperature coloring scheme, where
24 blue indicates ordered regions with low predicted per-residue errors and red indicates
25 high per-residue errors and more flexibility. **(B)** Schematic representation of the
26 designed ⁶²Gap27 sequence on Cx62. The topological diagram of the Cx62 protomer, the
27 predicted binding site (BS) is highlighted in orange. (NT: NH₂-terminus, CL: Cytoplasmic
28 loop, CT: COOH-terminus, T: Transmembrane, E: Extracellular) **(C)** Surface
29 representation of Cx62 hemichannels being targeted by ⁶²Gap27 showing the pore cross-
30 section and side views respectively. **(D)** Inter-protomer interactions. The hemichannel
31 formed by six protomers of Cx62 is shown in grey ribbon view, the side-chains in the
32 zoomed views are shown as sticks with brown and yellow colors to differentiate between
33 the residues of interacting protomer pairs. **(E)** Modeled intercellular interactions
34 between docked hemichannels. In the left-hand panel, a Cx62 gap junction channel is
35 shown. The region enclosed by dashed lines is sectioned perpendicular to the pore axis
36 and is viewed from the pore axis (right-hand panel). The interactions between the 2
37 docked hemichannels (the first external loop (E1) and the second external loop (E2)
38 regions) are depicted in the close-up images. In region E1, Gln58 forms symmetrical
39 hydrogen bonds with the same residue from the opposite protomer while Asn55 forms a
40 hydrogen bond with Arg57 in the opposite protomer. In region E2, Asn196 and Asp199
41 form hydrogen bonds with the same residues on the opposite protomer. **(F)** The efflux of

1 calcein from human platelets was measured using flow cytometric analysis. Calcein
2 loaded platelets incubated with ⁶²Gap27 or scrambled peptide (100 µg/ml) were
3 stimulated with thrombin (0.1 U/ml). Representative histograms of calcein fluorescence
4 for unstimulated (green), and thrombin-stimulated platelets in the presence of scrambled
5 (blue) or ⁶²Gap27 (100µg/ml) (orange) (n=4). **(G)** Calcein efflux following thrombin
6 stimulation for varying time periods was measured by the rate of fluorescence reduction
7 in platelets. Median fluorescence intensity for unstimulated and stimulated samples
8 treated with scrambled or ⁶²Gap27 was analyzed (n=4). **(H)** Calcein loaded platelets were
9 treated with scrambled or ⁶²Gap27 (100µg/ml) for 5 minutes before their stimulation on
10 fibrinogen and collagen-coated coverslips and FRAP analysis was performed.
11 Representative images represent fluorescence recovery (Pre-bleach, At-bleach and Post-
12 bleach) in samples treated with scrambled or ⁶²Gap27. Data represent Mean ± SEM,
13 ****P<0.0001 was calculated by two-way ANOVA. **(I)** Quantified data shows mean
14 fluorescence recovery intensity of scrambled and ⁶²Gap27 treated samples and
15 normalized to the level of fluorescence at bleach point (shown in red circles; panel G)
16 (n=5).

17

18 **Figure 3. ⁶²Gap27 inhibits platelet activation and function specifically through**
19 **Cx62.** Washed human platelets (4×10⁸ cells/mL) were treated with ⁶²Gap27 or scrambled
20 peptide (S; 100 µg/ml) for 5 minutes prior to their stimulation with **(A)** CRP-XL (EC₅₀: 0.2
21 - 0.4 µg/ml) or **(B)** Thrombin (EC₅₀: 0.05 - 0.08 U/ml). Aggregation was measured using
22 optical light transmission aggregometry for 180 seconds. Representative aggregation
23 traces and quantified data shown (Scrambled-treated samples represent 100%
24 aggregation). **(C)** Effects of ⁶²Gap27 on CRP-XL (0.25 µg/ml) and thrombin (0.05 U/ml)
25 mediated fibrinogen binding in comparison to the scrambled peptide (S; 100 µg/ml) was
26 evaluated in platelets (in PRP) using flow cytometry. **(D)** PRP from Cx57^{+/+} and Cx57^{-/-}
27 mice was treated with ⁶²Gap27, ^{37,43}Gap27, ⁴⁰Gap27 (100 µg/ml) or scrambled peptide (S;
28 100 µg/ml) for 5 minutes. Fibrinogen binding levels were evaluated after stimulation with
29 CRP-XL (1 µg/ml). **(E)** PRP from Cx57^{+/+} and Cx57^{-/-} mice was stimulated with CRP-XL (1
30 µg/ml) and fibrinogen binding was measured. **(F)** P-selectin exposure was measured in
31 ⁶²Gap27 or scrambled peptide (S; 100 µg/ml) treated human platelets (in PRP), following
32 stimulation with CRP-XL (0.25 µg/ml) or thrombin (0.05 U/ml). **(G)** Changes in ATP
33 release were monitored for 5 minutes in washed platelets (4 x 10⁸ cells/ml) incubated
34 with ⁶²Gap27 or scrambled peptide (S; 100 µg/ml) and stimulated with CRP-XL (0.5
35 µg/ml) or thrombin (0.05 U/ml). **(H)** The levels of TxB₂ were measured by immunoassay
36 in human washed human platelets (4×10⁸ cells/mL) treated with scrambled peptide (S;
37 100 µg/ml) or ⁶²Gap27 following stimulation with CRP-XL (0.5 µg/ml) or thrombin (0.05
38 U/mL). Data represent mean ± SEM (n≥3), *P<0.05, **P<0.01 and ***P<0.001 was
39 calculated by one-way ANOVA. †P<0.05 was calculated by the Student t-test.

Figure 4. ⁶²Gap27 inhibits integrin α IIb β 3-mediated signaling, thrombosis and hemostasis. **(A)** Human washed platelets (2×10^7 cells/mL) incubated for 5 minutes with ⁶²Gap27 (50 and 100 μ g/ml) or scrambled peptide (S; 100 μ g/ml) were exposed to fibrinogen (100 μ g/mL) coated coverslips. Representative images of spreading and adhesion of platelets after 45 minutes and cumulative data of platelets adhered to fibrinogen in each sample are shown. Spreading platelets were categorized into 3 groups (adhered but not spread; filopodia: platelets in the process of extending filopodia; and lamellipodia: fully spread). **(B)** To measure clot retraction, human PRP was incubated with ⁶²Gap27 (50 and 100 μ g/ml) or scrambled peptide (S; 100 μ g/ml) for 5 minutes prior to the initiation of clot formation by the addition of thrombin (1 U/ml). The extent of clot retraction was determined by comparing clot weight after 60 minutes. **(C)** DiOC6-loaded human whole blood was treated with scrambled peptide or ⁶²Gap27 (100 μ g/ml) for 5 min before perfusion through collagen-coated (100 μ g/mL) Vena8Biochips at an arterial shear rate of 500 s^{-1} (20 dyne/cm²). Representative images display thrombus formation at the end of the assay (10 mins) and quantified data represent mean thrombus fluorescence intensity. **(D)** *In vivo* thrombosis was assayed by intravital microscopy following the laser-induced injury. ⁶²Gap27 or scrambled peptide (100 μ g/ml) was administered intravenously to mice, and platelets were fluorescently labeled with Alexa-647-conjugated anti-GPIb antibody. After laser injury, platelet accumulation and thrombus formation were assessed. Representative images at different time-points are shown and data are expressed as median fluorescence intensity. **(E)** The mean of maximum fluorescence intensity was calculated from the maximum fluorescence intensity of each thrombi. A total of 21 thrombi were analyzed from 5 mice treated for each condition. **(F)** Tail bleeding as determined by time to cessation of bleeding in mice treated with scrambled peptide (S) or ⁶²Gap27 (100 μ g/ml) for 5 min (n=9 for scrambled peptide-treated and n=10 for ⁶²Gap27-treated samples). **(G)** The amount of blood loss was evaluated after the cessation of tail bleeding in mice treated with scrambled peptide or ⁶²Gap27 (100 μ g/ml) for 5 min. Data represent mean \pm SEM (n \geq 3), *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 was calculated by one-way ANOVA (spreading assay), two-way ANOVA (*in vitro* thrombus formation assay), nonparametric Mann-Whitney U test (*in vivo* thrombosis and blood loss in tail-bleeding assay) and Fisher's Exact test (time to cessation of bleeding in tail bleeding assay).

Figure 5. ⁶²Gap27 inhibits GPVI signaling in human platelets. ⁶²Gap27 (50 and 100 μ g/ml) or scrambled peptide (S, 100 μ g/ml) pre-treated human washed platelets (4×10^8 cells/mL) were stimulated for 90 seconds with CRP-XL (1 μ g/ml) under non-aggregation conditions in the presence of indomethacin (20 μ M), cangrelor (1 μ M), MRS2179 (100 μ M) and EGTA (1 mM). Samples were lysed in the Laemmli sample buffer, separated by SDS PAGE and transferred to PVDF membranes and were tested for **(A)** total tyrosine phosphorylation **(B)** Syk phosphorylation (Tyr^{525/526}), **(C)** LAT phosphorylation (Tyr²⁰⁰) **(D)** PLC γ phosphorylation (Tyr¹²¹⁷) and **(E)** PKC substrate phosphorylation. Representative blots for the phosphorylation levels are shown. The bar graph represents

mean normalized phosphorylation values relative to actin or 14-3-3- ζ levels. **(F)** FURA-2 AM-loaded washed platelets (4×10^8 cells/mL) were treated with $^{62}\text{Gap27}$ or scrambled peptide (S; 100 $\mu\text{g}/\text{ml}$) for 5 minutes prior to stimulation with CRP-XL (0.25 $\mu\text{g}/\text{mL}$). Spectrofluorimetry was used to measure the release of calcium from intracellular stores. Representative traces of calcium mobilization over a period of 5 minutes and quantified data (peak calcium levels) are shown. Results are mean \pm SEM ($n \geq 3$), $*P < 0.05$ and $**P < 0.01$ was calculated by one-way ANOVA.

Figure 6. Deletion of Cx57 reduced GPVI signaling in platelets. $^{62}\text{Gap27}$ (50 and 100 $\mu\text{g}/\text{ml}$) or scrambled peptide (S, 100 $\mu\text{g}/\text{ml}$) pre-treated Cx57 $+/+$ (WT) and Cx57 $-/-$ (KO) washed platelets (4×10^8 cells/mL) were stimulated for 90 seconds with CRP-XL (1 $\mu\text{g}/\text{ml}$) under non-aggregation conditions in the presence of indomethacin (20 μM), cangrelor (1 μM), MRS2179 (100 μM) and EGTA (1 mM). Samples were lysed in the Laemmli sample buffer, separated by SDS PAGE and transferred to PVDF membranes and were tested for **A)** total tyrosine phosphorylation and **B)** Syk phosphorylation (Tyr^{525/526}), **C)** LAT phosphorylation (Tyr²⁰⁰) and **D)** PLC γ phosphorylation (Tyr¹²¹⁷) and **E)** PKC substrate phosphorylation. Representative blots for the phosphorylation levels are shown. The bar graph represents mean normalized phosphorylation values relative to actin or 14-3-3- ζ levels. Results are mean \pm SEM ($n \geq 3$), $*P < 0.05$ and $***P < 0.001$ was calculated by one-way ANOVA.

Figure 7. $^{62}\text{Gap27}$ modulates PKA activity independently of cAMP. **(A)** Resting and **(B)** CRP-XL stimulated (90 seconds) washed human platelets (4×10^8 cells/mL) treated with scrambled peptide (S; 100 $\mu\text{g}/\text{mL}$) or $^{62}\text{Gap27}$ (50 and 100 $\mu\text{g}/\text{mL}$) for 5 minutes were tested for VASP S157 phosphorylation (a marker of PKA activity). VASP S157 phosphorylation was also evaluated in washed platelets treated with $^{62}\text{Gap27}$ (100 $\mu\text{g}/\text{mL}$) for 5 minutes in the presence of **(C)** H89 (10 μM), **(D)** PKI (10 μM) **(F)** Rp-8-CPT-cAMPS (200 μM), **(G)** SQ 22536 (100 μM). Platelets treated with PGI₂ (1 $\mu\text{g}/\text{mL}$) for the stimulation of PKA-mediated phosphorylation were used as positive controls. The lysis of the samples was carried out using the Laemmli sample buffer prior to separation by SDS-PAGE, then the samples were transferred to PVDF membranes. 14-3-3- ζ was detected a loading control. **(E)** Levels of cAMP were measured in resting and CRP-XL (1 $\mu\text{g}/\text{ml}$) stimulated washed human platelets (4×10^8 cells/mL) that had been pre-incubated with the scrambled peptide (S; 100 $\mu\text{g}/\text{mL}$) or $^{62}\text{Gap27}$ (50 or 100 $\mu\text{g}/\text{mL}$) for 5 minutes. PGI₂ (1 $\mu\text{g}/\text{ml}$) treated platelets were used as a positive control. **(H, I)** Resting washed platelets (4×10^8 cells/mL) from Cx57 $^{+/+}$ and Cx57 $^{-/-}$ mice were treated with scrambled peptide (S) or $^{62}\text{Gap27}$ (100 $\mu\text{g}/\text{mL}$) for 5 minutes in the presence of H89 (10 μM) or Rp-8-CPT-cAMPS (200 μM) and investigated for VASP-S157 phosphorylation. Platelets treated with PGI₂ (1 $\mu\text{g}/\text{mL}$) were used as a positive control. Results are mean \pm SEM ($n \geq 4$). $**P < 0.01$ and $***P < 0.001$ was calculated by one-way ANOVA.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7



Supplemental information

Structural, Functional and Mechanistic Insights Uncover the Fundamental Role of Orphan Connexin 62 in Platelets

Authors

Khaled A. Sahli,^{1,2}* Gagan D. Flora,^{1,3}* Parvathy Sasikumar,^{1,4} Ali H. Maghrabi,¹ Lisa-Marie Holbrook,^{1,5} Sarah K. AlOuda,¹ Amro Elgheznawy¹, Tanya Sage,¹ Alexander R. Stainer,¹ Recep Adiyaman,¹ Mohammad AboHassan,¹ Marilena Crescente,^{1,6} Neline Kriek¹, Sakthivel Vaiyapuri^{1,7}, Alexander P. Bye,¹ Amanda J. Unsworth^{1,8}, Christopher I. Jones¹, Liam J. McGuffin,¹ Jonathan M. Gibbins¹

KAS and GDF contributed equally to this study and are joint first authors

Materials

Cx62 antibody was obtained from Sigma-Aldrich. The anti-phosphotyrosine antibody 4G10 was obtained from Millipore, USA and the phospho-specific antibodies - PLC γ 2 (Y759), AKT (S473), myosin light chain (S19) and vasodilator-stimulated phosphoprotein (VASP) phospho-Ser157 and Ser239 were obtained from cell signaling technologies, USA. Syk (pY525/526) and LAT (Y200) antibodies were from Abcam. Anti-Phospho-PKC substrate antibody was purchased from New England BioLabs, USA. Mouse anti-human 14-3-3 ζ (Santa Cruz Biotechnology, USA) was used to detect 14-3-3 ζ to ensure equivalent levels of protein loading in immunoblots. The secondary antibodies used for immunoblotting; Cy5 goat anti-rabbit IgG, AlexaFluor488 goat anti-rabbit and AlexaFluor 488 goat anti-mouse IgG antibodies were obtained from Life Technologies, UK. All other reagents were from previously described sources¹⁻³.

Methods

Preparation of human Platelets

Human blood was taken from consenting, drug-free volunteers on the day of the experiment according to the methodology approved by the University of Reading Research Ethics Committee. Blood was taken using 3.8% (w/v) sodium citrate and Acid Citrate Dextrose (ACD; 110 mmol/L glucose, 80 mmol/L citric acid, 120 mmol/L sodium citrate) as an anticoagulant. Whole blood was centrifuged at 102g for 20 minutes at 20°C to yield platelet-rich plasma (PRP). Where washed platelets were required, they were isolated from the PRP by further centrifugation at 1413g for 10 minutes at 20°C in the presence of 0.1 μ g/ml prostacyclin to prevent activation. The supernatant was discarded in Klorsept disinfectant (Medentech, Wexford, Ireland) and the platelet pellet was resuspended in 25ml of modified Tyrodes-HEPES buffer (134 mmol/L NaCl, 0.34 mmol/L Na₂HPO₄, 2.9 mmol/L KCl, 12 mmol/L NaHCO₃, 20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl₂, pH 7.3) and 3 ml of ACD in the presence of 0.1 μ g/ml prostacyclin. Platelets were centrifuged at 1413g for 10 minutes at 20°C and resuspended to a density of 4x10⁸ cells/ml in modified Tyrodes-HEPES buffer using a platelet count obtained with a Z Series Coulter Counter (Beckman Coulter, CA, USA). Washed platelets were rested for at least 30 minutes at 30°C prior to the experiment to allow

responses to recover. Platelet preparations typically contained fewer than 1 contaminating erythrocyte or leukocyte per 6500 platelets.

ADP-sensitive washed platelets were prepared by collecting blood into 3.8% (w/v) sodium citrate and centrifugation at 102g for 20 minutes at 20°C to yield PRP (without the addition of ACD). Platelets were isolated from the PRP by further centrifugation at 350g for 20 minutes. The supernatant was discarded, and the platelet pellet was resuspended to a density of 4×10^8 cells/ml in the modified Tyrodes-HEPES buffer.

Preparation of Mouse Platelets

Mouse blood was collected through cardiac puncture after termination by rising CO₂ concentration and cervical dislocation as per Schedule 1 of the Animals (Scientific Procedures) Act 1986. After the mice were euthanized, their blood was drawn through the cardiac puncture into a syringe containing 4% sodium citrate (1 part sodium citrate to 9 parts blood). Red blood cells and leukocytes were eliminated by reducing the concentration of blood with Tyrode's-HEPES buffer followed by centrifugation at 203 g for 8 minutes. The upper layer comprising PRP was gently aspirated with a pipette. After the addition of PGI₂ (final concentration, 12.5 ng/mL) to the PRP, the platelets were subjected to centrifugation at 1,028 g for 5 minutes. The resulting platelet pellet was resuspended in modified Tyrode's-HEPES buffer (4×10^8 cells/mL) and left to rest at 30°C for 30 minutes.

Sucrose gradient sub-cellular fractionation

Platelet fractionation was performed as previously described with minor modifications⁴. Platelets were transferred into a cell-disruption bomb (Parr 4639, Parr Instrument Co.) and homogenized by nitrogen cavitation. A pressure of 1200 psi was applied with N₂ to the platelet suspension and after 15 min the pressure was quickly released. This procedure was repeated three times and the final platelet homogenate was cleared from the cell debris and partially disrupted cells by centrifugation at 500g for 10 min. The platelet homogenate was fractionated over a linear sucrose gradient (from 60 to 30%, w/v in 5mM EDTA) by centrifugation at 284,061 x g for 2 hours at 4°C. Fractions were collected from the top of the tube and aliquots analyzed by immunoblotting.

Immunofluorescence microscopy

Human blood was collected in vacutainers containing sodium citrate as described previously. The blood was centrifuged at 100g for 20 minutes to collect PRP. Resting or activated platelets (stimulated with 5 μ M U46619; in the presence of 4 μ M integrillin) in PRP were fixed with an equal volume of 8% paraformaldehyde-PBS (PFA-PBS) to make a final concentration of 4% (v/v) and incubated for 15 min. Thereafter, platelets were centrifuged at 950g for 10 minutes. The supernatant was removed, and the platelet pellet was resuspended in 2 ml of PBS-ACD (pH 6.1) for washing. Platelets were centrifuged for 10 minutes at 950g and resuspended in 1 ml of PBS-ACD to concentrate platelets. Platelets were centrifuged again at the same speed for 10 minutes and then resuspended in 500 μ l of 1% (w/v) BSA-PBS, to concentrate platelets even more. Poly-L-lysine coated-12mm coverslips (VWR micro cover glass No.1.5) were put in a 6x6 culture plate and 90 μ l of platelets were added on each coverslip. Culture plates were placed at 37°C for 90 minutes. After 2-3 washes with PBS, samples were blocked with 0.2% (v/v) Triton-X-100, 2% (v/v) serum from same species as secondary antibody and 1% (w/v) protease-free BSA for 1h. Thereafter, primary antibodies diluted (1:100) in 0.2% (v/v) Triton-X-100, 2% (v/v) serum from the same species as secondary antibody and 1% (w/v) protease-free BSA were added and left overnight. The following day, samples were washed with PBS (2-3 times) and secondary antibodies (1:200) were added for 1 hour at room temperature. The unbound antibodies were washed off with PBS (2-3 times) and samples were fixed using 4% (v/v) PFA-PBS for 5 minutes. The coverslips were washed again with PBS (2-3 times). Coverslips were placed on glass slides after adding ProLong Gold Antifade mounting media (Life technologies). The slides were kept at room temperature until mounting media dried and then kept in the fridge until they were imaged using a Nikon A1-R confocal microscope (100x oil immersion).

Stochastic optical reconstruction microscopy (STORM)

Tyrode's-HEPES buffer was used to dilute the PRP (1:20). The polymerization of fibrin was prevented by treatment with GPRP (0.5 mg/mL). The samples were activated with thrombin (1 U/mL) for 5 minutes, then the unstimulated and stimulated samples were fixed with 2% (v/v) formyl saline and subjected to centrifugation for 15 minutes at 500 g. After removal of the supernatants, the pellets containing the platelets were resuspended in Perm Buffer III (100 μ L; BD Biosciences, Oxford, UK) and incubated on ice for 30 minutes. Platelets were then washed with Tyrode's-HEPES buffer (2 \times 20 minutes) and subjected to centrifugation at 500 g. The supernatant

was discarded, and the resultant pellet was resuspended in Tyrode's-HEPES buffer (50 μ L). The samples were incubated with the primary antibodies (diluted 1:50; mouse monoclonal IgG against integrin β_3 and rabbit polyclonal IgG against Cx62) at 4 °C overnight. Platelets were then washed twice with Tyrode's-HEPES buffer (2 mL) followed by centrifugation for 20 minutes at 550 *g*. The samples were incubated with secondary antibodies (diluted 1:50 in Tyrode's-HEPES buffer; Alexa Fluor® 647-labeled donkey anti-rabbit to detect Cx62 and Alexa Fluor® 555-labeled goat anti-mouse to detect β_3 integrin) at 37 °C for 30 minutes. Platelets were then washed with Tyrode's-HEPES buffer (2 mL) and subjected to centrifugation for 20 minutes at 550 *g*. The resulting pellet was suspended in Tyrode's-HEPES buffer (100 μ L). Finally, platelets (100 μ L) were applied to the ibidi® slides coated with poly-L-lysine. The slides were incubated at 4 °C overnight to allow the platelets to adhere. The next day, the unbound platelets were removed and blinking buffer was added (Stock A: 0.90 g/mL catalase [Sigma–Aldrich], 0.182 mM Tris [2-carboxyethyl] phosphine hydrochloride [Sigma–Aldrich], 2.27% [v/v] glycerine, 1.14 mM KCl, 0.91 mM Tris-HCl [pH 7.5], 0.045 mg/mL glucose oxidase [Sigma–Aldrich] and 5 mL diH₂O; stock B: 36 mg/mL glucose, 3.6% [v/v] glycerine and 36 mL H₂O; and stock C: 0.09 M mercaptoethylamine-HCl [Sigma–Aldrich] and 1 mL diH₂O). For 3D STORM imaging of the platelets, the 100 \times oil immersion lens of the microscope was used.

Coordinate-based colocalization (CBC) analysis⁵ was performed to assess changes in the colocalization of Cx62 and β_3 integrin upon platelet stimulation using ImageJ and the open-source Thunderstorm plugin.⁶

Calcein Dye Efflux

Platelets (in PRP) were loaded with calcein-AM (0.5 μ M; Thermo Fisher Scientific, Waltham, MA, USA) for 30 minutes at 37 °C as described previously⁷. The platelets were then treated with scrambled peptide or ⁶²Gap27 for 5 minutes. Next, the platelets were stimulated with thrombin (0.1 U/mL). In order to prevent fibrin polymerization, the thrombin-treated samples were also treated with GPRP (25 μ g/mL). Stimulation was carried out with gentle mixing for different time periods over 5 minutes. Finally, the reaction was stopped with 0.2% (v/v) formyl saline. Flow cytometry (488 nm excitation, 530 \pm 30 nm emission) was performed with a BD Accuri™ C6 flow cytometer (BD Biosciences, Oxford, UK). For each sample, 10,000 events, gated on platelets by

forward scatter and side scatter, were collected. Data were analyzed with the built-in BD Accuri™ C6 Plus software (version 1.0.264.21).

Fluorescence Recovery after Photobleaching (FRAP)

FRAP analysis was performed as previously described with minor modifications^{8,9}. Each of eight wells of each ibidi® slide was coated with fibrinogen (100 µg/mL) and collagen (10 µg/mL) in modified PBS for 1 hour. 1% (w/v) BSA was added to the wells followed by a 1-hour incubation to prevent the binding of platelets to the glass. The wells were washed three times with PBS. Calcein-loaded PRP was added to the coated coverslips and incubated for 45 minutes. Unbound platelets were washed from the wells with PBS (three washes). The samples were then treated with the scrambled peptide or ⁶²Gap27 (100 µg/mL) for 5 minutes. A high-intensity laser (488 nm) was trained on the central circular area (8-µm-diameter region of interest [ROI]) of the monolayer of cells thrombus for 300 milliseconds, resulting in an 85% loss of fluorescence. Then, a 488-nm wavelength laser was used to excite the samples and the fluorescence emission was detected at 500–520 nm. Finally, fluorescence recovery was recorded for 500 seconds. The 100× oil immersion objective of an A1R confocal microscope was used to capture images of single sections every second for 500 seconds. Five thrombi from each of seven donor samples treated with scrambled peptide or ⁶²Gap27 were analyzed. NIS-Elements software (Nikon, Tokyo, Japan) was used to compute the mean fluorescence intensities. For each time point, the average fluorescence intensities were computed for the background, non-bleached (reference) and bleached areas.

Protein Bioinformatics

The complete sequence of Cx62 was obtained from GenBank¹⁰, and for the physicochemical analysis, ProtParam¹¹ was utilized. In the absence of an experimental structure, state-of-art structure prediction tools were employed to obtain 3D models for the Cx62 protomer. The IntFOLD4-TS method¹² from the IntFOLD server¹³ was used to predict tertiary structure models for the Cx62 protomer (monomeric subunit). Additionally, the quality estimation method, ModFOLD6¹⁴, was employed to provide both global and local (per-residue) scores for estimating 3D model quality. The calculated local (or per-residue) errors from ModFOLD6 were mapped onto the model using the temperature coloring scheme ranging from blue (indicating residues modeled

with high quality) to red (indicating residues with lower model quality, which are often more flexible or disordered).

Multiple sequence alignment of human connexin sequences was performed using ClustalW to ensure the selectivity of 62Gap27. A scrambled peptide control was designed using Mimotopes, (<http://www.mimotopes.com/peptideLibraryScreening.asp?id=97>) and BLAST searches performed to ensure that designed sequences were not present in any other proteins.

To predict the most likely interactions occurring between Cx62 and the ⁶²Gap27 inhibitor, protein-ligand docking was performed using the SwissDock server¹⁵. The FullFitness and Gibbs free energy (ΔG) score of each run of the docking was evaluated and the final ranking of each cluster was based on the FullFitness scores.

The quaternary structures of the Cx62 hemichannels (2x 6-mers) were successfully modeled using the PDB entry 2zw3 (crystal structure of Cx26 gap junction) as a template. The docked hemichannel assembly (12-mer) template for PDB ID 2zw3 was downloaded from PISA ¹⁶ service at the EBI (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html). For each hemichannel, the template was used to orientate six of the modeled protomers by a six-fold symmetry axis perpendicular to the membrane plane and build the complete model of the docked hemichannel (12-mer) complex. Residues in the modeled protein-protein and protein-ligand complexes were considered to be interacting if the distance between the closest heavy atoms (i.e. non-hydrogen) in the residues belonging to different chains was $\leq 5\text{\AA}$.

Platelet aggregometry

Light transmission aggregometry (LTA) was performed in an optical platelet aggregometer (Chrono-Log, PA, USA, and Helena Biosciences Europe, Gateshead, UK). Washed platelets (4×10^8 cells/ml) treated with ⁶²Gap27 or scrambled peptide were stimulated in the presence of agonist (collagen, CRP-XL, thrombin, U46619 or ADP) with continuous stirring (1200 rpm at 37°C) for 3 minutes and aggregation was measured as an increase in light transmittance. The data were quantified by considering scrambled peptide-treated samples as 100% aggregation and the level of aggregation obtained in scrambled peptide-treated samples was normalized to it.

Fibrinogen binding and alpha granule secretion

Fibrinogen binding and P-selectin exposure to the platelet surface were detected by flow cytometry as measures of integrin $\alpha\text{IIb}\beta\text{3}$ activation and the secretion of α -granules respectively. Fluorescein isothiocyanate (FITC)-labelled rabbit anti-human fibrinogen antibody (Dako, Ely, UK) was used to measure fibrinogen binding. PE-Cy[™] 5-labeled mouse anti-human CD62P antibody (BD Biosciences, Oxford, UK) was used to measure the exposure of P-selectin. The assay volume comprising human or mouse PRP, an inhibitor of Cx function or appropriate scrambled peptide control and each of the antibodies in modified Tyrode's-HEPES buffer, was incubated for 5 minutes at room temperature in the dark. The platelet agonists thrombin (in the presence of GPRP to prevent fibrin polymerization) or CRP-XL were added and incubated for an additional 20 minutes. The reaction was stopped by the addition of 0.2% (v/v) formyl saline. A BD Accuri[™] C6 flow cytometer (BD Biosciences, Oxford, UK) and BD Accuri[™] C6 software were used for the acquisition of the flow cytometry data. The median fluorescence intensity was calculated for 10,000 gated events. Fluorescence in FL1-A and FL3-A channels were used to analyze fibrinogen binding and P-selectin exposure, respectively.

Dense granule secretion

Dense granule secretion was determined by measuring changes in the extracellular ATP concentration. These changes were observed concurrently with aggregation in a Model 700 Whole Blood/Optical Lumi-Aggregometer with the use of a luciferase kit (Chrono-Log, Havertown, PA, USA). ATP release from dense granules was monitored with a bioluminescence system comprising D-luciferin, firefly luciferase and magnesium. ATP interactions with these reagents produce light, in direct proportion to the ATP concentration, which is observed and quantified using a Lumi-aggregometer. Platelets (4×10^8 cells/mL) were pre-treated with ⁶²Gap27 or scrambled peptide at 37°C for 5 minutes. Luciferase was added under stirring conditions during the last 2 minutes of the incubation. The platelets were stimulated with the indicated concentrations of thrombin or CRP-XL under stirring conditions (1,200 rpm at 37°C). ATP release and aggregation at 37°C were recorded for 3 minutes following the addition of agonist using the AggroLink8 software, which calculates ATP secretion levels from the 2nM ATP standard.

TxB₂ Assay

The TxB₂ measurements were performed with a TxB₂ immunoassay kit based on a competitive ELISA (Cayman Chemical, Cambridge, UK), according to the manufacturer's instructions. Washed platelets (4×10^8 cell/mL) were treated with ⁶²Gap27 or scrambled peptide for 5 minutes in glass cuvettes. The samples were then activated with CRP-XL or thrombin. After 5 minutes, stop solution (1 mM EGTA and 10 μM indomethacin) was added to terminate the reaction. The samples were then immediately subjected to centrifugation for 2 minutes at 12,000 rpm and the supernatants were frozen at -80°C. Later, the supernatants were thawed and diluted 1:40 in ELISA buffer (0.01% [w/v] sodium azide, 1 mM EDTA, 400 mM NaCl, 0.1% [w/v] BSA and 100 mM phosphate). The dilutions were plated in wells coated with polyclonal goat anti-mouse IgG antibodies. To determine the relationship between the TxB₂ concentration and absorbance, TxB₂ standards were prepared. TxB₂-acetylcholinesterase and anti-TxB₂ monoclonal antibody were added to each well, then the plate was incubated at room temperature for 2 hours. After incubation, the plate was washed 4 times with washing buffer. Next, Ellman's reagent was added to each well and the plate was incubated in the dark. A NOVOstar plate reader (BMG Labtech, Aylesbury, UK) was used to determine the absorbances of the wells at 405 nm. A standard curve was plotted using the absorbance readings for the TxB₂ standards. The inverse function was used to compute the TxB₂ concentrations from the test sample readings.

Measurement of intracellular calcium mobilization

The mobilization of Ca²⁺ from intracellular stores into the platelet cytosol was measured in a fluorescence-based 96-well plate assay. PRP was incubated with 2 μM Fura-2 AM for 60 minutes at 30°C. The PRP was washed and subjected to centrifugation at 350 *g* for 20 minutes, then resuspended in modified Tyrode's-HEPES buffer containing CaCl₂ (1mM) at 4×10^8 cell/mL. Fura-2-loaded platelets were incubated with ⁶²Gap27 or scrambled peptide for 5 minutes at 37°C, then stimulated with the agonists, CRP-XL or thrombin. A NOVOstar plate reader (BMG Labtech, Aylesbury, UK) was used to measure the fluorescence (excitation at 340 and 380 nm and emission at 510 nm). The ratio of the excitation signals at 340 and 380 nm was used to estimate the concentration of Ca²⁺. To measure the mobilisation of calcium from intracellular stores, the

above-mentioned steps were performed using Fura-2 loaded washed platelets (in the absence of 1 mM CaCl₂) in the presence of saturating concentration of EGTA (2mM).

The cells were lysed with digitonin (5 μM) to release the Fura-2 into the assay buffer (which contained 1 mM CaCl₂) and facilitate the measurement of the maximum fluorescence ratio. The minimum fluorescence ratio was measured by chelating Ca²⁺ ions with EGTA (10 mM) and Tris base (10 mM; added to ensure that the pH remained alkaline for optimum Ca²⁺ buffering by EGTA). Non-Fura-2-loaded cells at the same final density were used to measure the autofluorescence levels. Using the calibration values from above, experimental [Ca²⁺]_i concentrations were calculated using the following equation:

$$[Ca^{2+}]_i = K_d \times \frac{S_f}{S_b} \times \frac{R - R_{min}}{R_{max} - R}$$

Where K_d is the dissociation constant of Fura-2AM (~224 nM). S_f and S_b are the values of the fluorescence at 380nm excitation (corrected to background auto-fluorescence), with zero or saturating [Ca]²⁺ respectively. R is the 340/380nm fluorescence ratio, corrected for background fluorescence. R_{min} and R_{max} are the ratio limits at zero or saturating [Ca]²⁺, respectively, adjusted using a viscosity constant of 0.85. This corrects for the effects of the cellular environment on the fluorescence of Fura-2.

Platelet adhesion and spreading

To study platelet spreading, glass coverslips coated with fibrinogen (100 μg/mL in modified PBS) were placed in 6-well plates. After coating for 1 hour, 1% (w/v) BSA was added to the coverslips followed by 60 minutes incubation to prevent platelets from binding the glass. The coverslips were then washed three times with PBS. The washed platelet suspensions (2 × 10⁷ cells/mL) that had been incubated for 5 minutes with ⁶²Gap27 or scrambled peptide were then added to the coverslips and incubated at 37°C for 45 minutes. Unbound platelets were removed, and the coverslips were washed three times with PBS. Then, the coverslips were fixed in 0.2% (v/v) formal saline for 10 minutes. The coverslips were again washed three times with PBS. Next, the platelets were permeabilized with 0.2% (v/v) Triton™ X-100 for 5 minutes, then washed three times with PBS. The coverslips were incubated with Alexa Fluor® 488-conjugated phalloidin for 1 hour in the dark to label filamentous actin. The supernatants were removed, the coverslips were washed with PBS and placed on glass slides and fluorescence was preserved by adding ProLong™ Gold Antifade

Mountant. The 100× oil immersion lens of the Nikon A1R confocal microscope (Nikon, Tokyo, Japan) was used to image samples (excitation at 488 nm from an argon laser, emission between 500 and 520 nm). Images were taken in a single focal plane. In order to determine platelet adhesion, the numbers of platelets in five random images of each coverslip were counted. Platelets were categorized as spread fully (lamellipodia formed), partially spread (defined as filopodia) or adhered (not spreading). Finally, the relative frequencies of these groups were computed.

Clot retraction

Human PRP was prepared and rested at 30°C for 30 minutes. Red blood cells and ⁶²Gap27 or scrambled peptide were mixed with the PRP. The mixture was adjusted to a final volume of 1 mL with modified Tyrode's-HEPES buffer and incubated for 5 minutes at room temperature. Thrombin (final concentration, 1 U/mL) was added to initiate clot generation. A glass pipette was added to the center of each test tube, around which the clot would form, and samples were placed in an incubator chamber at 37°C. Photographs were taken every 10 minutes and the assay was terminated after 60 minutes at which time the clot in the scrambled peptide-treated samples was seen to have retracted completely. Clot weight was measured as a marker for clot retraction. Clots were removed from the glass pipettes and transferred into the pre-weighed microfuge tubes. Clot mass was determined by subtracting the weight of pre-weighed microfuge tubes from the weight of microfuge tubes containing clot.

***In vitro* thrombus formation under flow**

Whole human blood was incubated with the lipophilic dye DiOC6 (5 μM) at 30 °C for 1 hour. Vena8 BioChip microfluidic channels were coated with type I collagen (100 μg/mL) for 1 hour. Channels were washed with modified Tyrode's-HEPES buffer to remove excess collagen. Whole blood was incubated with ⁶²Gap27 or scrambled peptide for 5 minutes. Then, the blood samples were perfused through the collagen-coated channels at an arteriolar shear rate of 20 dyne/cm². An argon laser was used to excite fluorescence (488 nm) and emission was recorded at 500–520 nm. Thrombus formation on the microfluidic chip was observed through the 20x objective of the Nikon A1R confocal microscope. Images of single sections were obtained every second for 600 seconds. Finally, NIS-Elements software (Nikon, Tokyo, Japan) was used to compute the mean thrombus fluorescence intensity.

***In vivo* thrombus formation**

C57BL/6 mice were anaesthetised with intraperitoneally administered atropine (0.25 mg/kg), xylazine (12.5 mg/kg) and ketamine (125 mg/kg). When needed, pentobarbital (5 mg/kg) was used to sustain anesthesia. After the exteriorization of the cremaster muscle and removal of the connective tissue, an incision was made in the muscle, resulting in its adherence as a single layer to the glass slide. A buffer (135 mM NaCl, 4.7 mM KCl, 2.7 mM CaCl₂ and 18 mM NaHCO₃; pH 7.4) was used to hydrate the muscle.

Before the injury (made with a MicroPoint Ablation Laser Unit; Andor Technology, Belfast, UK), ⁶²Gap27 or scrambled peptide and DyLight® 649-conjugated anti-GPIIb/IIIa antibody (to label platelets; 0.2 µg/g mouse weight), were introduced into the circulation through a cannula in the carotid artery. After 5 minutes of administration of ⁶²Gap27 or scrambled peptide, the formation of thrombi was observed with an Olympus BX61W1 microscope (Olympus, Tokyo, Japan). A Hamamatsu digital camera (C9300; Hamamatsu Photonics, Welwyn Garden City, UK) with charge-coupled device camera in 640×480 format was used to obtain images before and after injury. The images were analyzed with SlideBook 6 software (Intelligent Imaging Innovations, Denver, CO, USA). The protocol from the Home Office license was followed for the sacrifice of the mice. The protocol was also approved by the Animal Welfare and Ethics Research Board and the University of Reading local ethics review panel.

Tail Bleeding Assay

C57BL/6 mice were anesthetized by intraperitoneal administration of xylazine (12.5 mg/kg) and ketamine (125 mg/kg). ⁶²Gap27 or scrambled peptide was administered through injection via the femoral vein. After 5 minutes of infusion, the tips of the tails (0.3 cm) were cut with a scalpel and immediately placed in tubes with saline in a manner that prevented the cut ends of the tails from touching the walls of the tubes. The bleeding time was recorded until blood flow stopped or for up to 20 minutes. The mice were sacrificed according to the protocol that was approved by the University of Reading local ethics review panel, the Animal Welfare and Ethics Research Board and the Home Office.

cAMP ELISA

A cAMP immunoassay kit based on a competitive ELISA (Cell Signaling Technology, Hitchin, UK) was used to assess cAMP levels, according to the protocol provided by the manufacturer. Washed platelets (4×10^8 cell/mL) were added to a glass cuvette and treated with $^{62}\text{Gap27}$ or scrambled peptide for 5 minutes. After 5 minutes of stimulation with CRP-XL or thrombin, lysis buffer (Triton™ X-100: 1% polyethylene glycol octylphenol ether) was added to the samples. The samples were immediately frozen at -20°C . The samples were later thawed and added to microwells coated with cAMP XP® rabbit monoclonal antibody. The association between cAMP concentration and absorbance was determined using cAMP standards. The assay plate was covered and incubated on a horizontal orbital plate shaker for 3 hours at room temperature. After incubation, the contents of the wells were removed and the wells were washed with 1x washing buffer three times. Then, 3,3',5,5'-tetramethylbenzidine substrate was added to the wells and the plate was incubated for 30 minutes. Stop solution was added to terminate the reaction. The absorbance at 450 nm was periodically determined with a NOVOstar plate reader (BMG Labtech, Aylesbury, UK). A standard curve was plotted from the absorbance readings of the cAMP standards. cAMP concentrations were computed for the test sample readings via the inverse function.

Western blotting


To study cell signaling, human or mouse washed platelets were prepared at a density of 4×10^8 cells/ml under non-aggregation conditions [indomethacin ($20 \mu\text{M}$), cangrelor ($1 \mu\text{M}$), MRS2179 ($100 \mu\text{M}$) and EGTA (1mM)]. These platelets were treated with an inhibitor of Cx function or scrambled peptide control for 5 minutes and then stimulated with platelet agonists in the aggregometer. Unstimulated or stimulated samples were lysed with 6X Laemmli sample reducing buffer and heated to 95°C for 5 minutes before storing at -20°C until use.

The proteins in the extracts of the platelet lysates were separated by SDS-polyacrylamide gel electrophoresis (PAGE) after heating to 95°C for 10 minutes in 6x Laemmli reducing buffer. The samples and molecular weight standards were loaded onto 4%–20% acrylamide gradient gels (Bio-Rad precast gels; Bio-Rad, Watford, UK). The gels were run at a constant voltage (100V) for 90 minutes in a Mini-PROTEAN® II apparatus (Bio-Rad, Watford, UK) with Tris-glycine buffer in the

running reservoir. The separated proteins were transferred to PVDF membranes (Bio-Rad, Watford, UK) by semi-dry transfer. PVDF membranes, soaked in methanol, were placed under the resolving gels. Four sheets of 3-mm filter paper soaked in anode buffer (300 mM Tris base and 20% [v/v] methanol; pH 10.4) were placed below the membranes and 4 sheets of 3-mm filter paper soaked in cathode buffer (25 mM Tris base and 40 mM 6-amino-n-hexanoic acid; pH 9.4) were placed above the resolving gels. The proteins were transferred from the gels to the membranes by applying a constant voltage (15V) for 2 hours.


The PVDF membranes were blocked with 5% (w/v) BSA dissolved in 1% (v/v) Tris-buffered saline–TWEEN® 20 for 1 hour at room temperature. The membranes were incubated with the primary antibodies, which were diluted in 1% (v/v) TBST with 2% (w/v) BSA, overnight at 4°C. After overnight incubation, the membranes were washed with TBST (3 × 5 minutes) to remove unbound antibodies. Fluorescently labeled secondary antibodies diluted in 1% (v/v) TBST containing 2% (w/v) BSA were then applied to the membranes, which were incubated for 1 hour at room temperature in the dark. The membranes were then washed with TBST (3 × 5 minutes) and their fluorescence visualized using a Typhoon FLA 9500 fluoroimager (Amersham Biosciences, Buckinghamshire, UK). Image Quant software version 8.1 (GE Healthcare) was used to quantify the fluorescence intensities of the individual bands.

Supplemental Figure 1




Supplemental Figure 1. Localization of Cx62 in platelets. **(A)** Treatment of platelets with secondary antibody alone (in the absence of anti-GJA10 primary antibody) was performed during STORM microscopy to exclude the possibility of non-specific staining **(B)** Cx62 is distributed in low-density subcellular platelet fractions. Ultracentrifugation was utilized to separate platelet homogenates on a sucrose density gradient. The fractions were separated by SDS-PAGE and immunoblotted for Cx62, β 3 integrin, calreticulin, RabGDIb and TSP-1. The lower-density platelet fractions (lanes 1–6) are identified by the DTS protein calreticulin, surface marker integrin β 3, and the cytosolic marker RabGDIb. The α -granule protein TSP-1 was used to identify the heavier fractions. A Typhoon™ FLA 9500 fluorimager was utilized to examine the immunoblots (GE Healthcare, UK). The results are representative of 3 individual experiments. WPL: whole platelet lysate. **(C)** Effects of $^{62}\text{Gap27}$ (100 $\mu\text{g}/\text{ml}$) on thrombin (0.1 U/ml) mediated P-selectin exposure, in comparison to the scrambled peptide (S; 100 $\mu\text{g}/\text{ml}$) was evaluated using flow cytometry. **(D)** Structural representation of the target region to which the $^{62}\text{Gap27}$ mimetic peptide was designed, and the putative binding site of the inhibitor on Cx62. Statistical analysis was performed using the student t-test.

Supplemental Figure 2



Supplemental Figure 2. $^{62}\text{Gap27}$ inhibits platelet aggregation and fibrinogen binding to integrin $\alpha\text{IIb}\beta3$. (A) Washed human platelets (4×10^8 cells/mL) were treated with vehicle (V; ddH₂O) or scrambled peptide (S; 100 $\mu\text{g/ml}$) and stimulated with CRP-XL or thrombin. Aggregation was measured using optical light transmission aggregometry for 180 seconds. Representative aggregation traces are shown (B, C) Washed human platelets (4×10^8 cells/mL) were treated with $^{62}\text{Gap27}$ or scrambled peptide (100 $\mu\text{g/ml}$) for 5 minutes prior to their stimulation with (B) U46619 (EC₅₀: 0.25–0.4 μM) or (C) ADP (EC₅₀: 5–10 μM). Aggregation was measured optical light transmission aggregometry for 180 seconds. Representative aggregation traces and quantified data shown (Scrambled-treated samples represent 100% aggregation) (D) Effects of the vehicle (V; ddH₂O) and scrambled peptide (S; 100 $\mu\text{g/ml}$) on CRP-XL (0.25 $\mu\text{g/ml}$) and thrombin (0.05 U/ml) mediated fibrinogen binding was evaluated in platelets (in PRP) using flow cytometry. Data represent mean \pm SEM ($n \geq 3$), ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ was calculated by one-way ANOVA.


Supplemental Figure 3



Supplemental Figure 3. Characterization of Cx57^{-/-} platelets. Cx57^{+/+} and Cx57^{-/-} platelets were used to evaluate the expression of (A) Cx37 and (B) Cx40 by immunoblotting. (C) Cx37^{+/+}, Cx37^{-/-} and (D) Cx40^{+/+},


Cx40^{-/-} platelets were used to analyze the expression of Cx57 by immunoblotting. Actin was used as a loading control. Quantified data shown. The expression levels of **(E)** GPVI **(F)** α2β1, **(G)** αIIbβ3 and **(H)** GPIb were analyzed in resting and CRP-XL-activated (1 μg/ml) platelets from Cx57^{+/+} and Cx57^{-/-} mice by flow cytometry. The student t-test was used for statistical analysis.

Supplemental Figure 4



Supplemental Figure 4. Cx57 functions independently of Cx37 and Cx40 in platelets. PRP from **(A)** Cx37^{+/+} and Cx37^{-/-} and **(B)** Cx40^{+/+} and Cx40^{-/-} mice was treated with ⁶²Gap27 (100 μg/ml) or scrambled peptide (S; 100 μg/ml) for 5 minutes. Fibrinogen binding levels were evaluated after stimulation with CRP-XL (1 μg/ml). **(C)** Effects of scrambled peptide (S; 100 μg/ml) and vehicle (V: ddH₂O) on CRP-XL (0.25 μg/ml) and thrombin (0.05 U/ml) mediated P-selectin exposure was evaluated in platelets (in PRP) using flow cytometry. **(D)** DiOC6-loaded human whole blood was treated with scrambled peptide or ⁶²Gap27 (100 μg/ml) for 5 min before perfusion through collagen-coated (100 μg/ml) Vena8Biochips at a shear rate of 500 s⁻¹ (20 dyne/cm²). Quantified data display surface coverage of thrombus over a period of 10 minutes. Data represent mean ± SEM (n≥3). *P<0.05 and **P<0.01 was calculated by the Student t-test. ##P<0.01 was calculated by two-way ANOVA.

Supplemental Figure 5



3
4
5
6
7
8

Supplemental Figure 5. ⁶²Gap27 inhibits thrombin-mediated signaling in human platelets. (A) Fura-2AM-loaded washed platelets (4×10^8 cells/mL) were incubated with ⁶²Gap27 (50 or 100 μg/mL) or scrambled peptide (S, 100 μg/mL) for 5 minutes in the presence of EGTA and stimulated with CRP-XL (0.5 μg/mL) for 5 minutes. Spectrofluorimetry was used to measure the release of calcium from intracellular stores. Representative traces of calcium mobilization over a period of 5 minutes and quantified data (peak calcium levels) are shown. **(B)** Representative blot and quantified data indicate the levels of phosphorylated total tyrosine in washed human platelets (4×10^8 cells/mL). Resting human platelets (R) were pre-incubated with scrambled peptide (S) or ⁶²Gap27 (100 μg/mL) for 5 min then were stimulated with thrombin (T; 0.05 U/ml). **(C)** Calcium mobilization and **(D)** release of calcium from intracellular stores was measured in Fura-2AM-loaded washed platelets (4×10^8 cells/mL) treated with scrambled peptide (S; 100 μg/mL) or ⁶²Gap27 and stimulated with thrombin (0.05 U/ml). Representative traces of calcium mobilization over a period of 5 minutes and quantified data (peak calcium levels) are shown. **(E)** Representative blot and quantified data indicate the levels of phosphorylated PKC substrate in washed human platelets (4×10^8 cells/mL). Resting human platelets (R) were pre-incubated with scrambled peptide (S) or ⁶²Gap27 (100 μg/mL) for 5 min then were stimulated with thrombin (T; 0.05 U/ml). **(F)** Representative blot and quantified data indicate the levels of pERK1/2 in washed human platelets (4×10^8 cells/mL). Resting human platelets (R) were pre-incubated for 5 minutes with Scrambled peptide (S) or ^{37,43}Gap27 or ⁶²Gap27 (100 μg/mL) and stimulated with thrombin (T; 0.05 U/ml) or CRP-XL (C; 1 μg/ml). Actin was used as a loading control. Data represent the mean ± SEM (n≥3). *P<0.05, **P<0.01, ****P<0.0001 and #####P<0.0001 was calculated by one-way ANOVA.

21

22

23

24

25

26

27

28

29


30

31

32

33

Supplemental Figure 6



Supplemental Figure 6. $^{62}\text{Gap27}$ modulates PKA activity. (A) Resting washed human platelets (4×10^8 cells/mL) treated with scrambled peptide (S; 100 $\mu\text{g/ml}$) or $^{62}\text{Gap27}$ (50 and 100 $\mu\text{g/ml}$) for 5 minutes were tested for VASP S239 phosphorylation (a marker of PKG activity). Platelets treated with PAPA-Nonoate (NO; 100 μM) for the stimulation of PKG-mediated phosphorylation were used as positive controls. (C) Resting washed human platelets (4×10^8 cells/mL) treated with scrambled peptide (S) or $^{37,43}\text{Gap27}$ or $^{62}\text{Gap27}$ (100 $\mu\text{g/ml}$) for 5 minutes were tested for VASP S157 phosphorylation. Platelets treated with PGI₂ (1 $\mu\text{g/ml}$) were used as a positive control. (D) Resting washed human platelets (4×10^8 cells/mL) were treated with GF109203X (10 μM), (E) LY29400 (100 μM) or (F) AKT inhibitor IV (5 μM) for 15 minutes before incubation with the scrambled peptide or $^{62}\text{Gap27}$ (100 $\mu\text{g/ml}$) for 5 minutes. Samples were assayed for VASP-S157 phosphorylation. 14-3-3- ζ was detected by immunoblotting as a loading control. Representative blots are shown. Data represent the mean \pm SEM ($n \geq 3$). * $P < 0.05$ was calculated by one-way.

1 References

2

- 3 1. Spyridon M, Moraes LA, Jones CI, et al. LXR as a novel antithrombotic target. *Blood*.
4 2011;117(21):5751-5761.
- 5 2. Unsworth AJ, Flora GD, Sasikumar P, et al. RXR Ligands Negatively Regulate Thrombosis
6 and Hemostasis. *Arterioscler Thromb Vasc Biol*. 2017;37(5):812-822.
- 7 3. Flora GD, Sahli KA, Sasikumar P, et al. Non-genomic effects of the Pregnane X Receptor
8 negatively regulate platelet functions, thrombosis and haemostasis. *Sci Rep*.
9 2019;9(1):17210.
- 10 4. Jonnalagadda D, Sunkara M, Morris AJ, Whiteheart SW. Granule-mediated release of
11 sphingosine-1-phosphate by activated platelets. *Biochim Biophys Acta*.
12 2014;1841(11):1581-1589.
- 13 5. Malkusch S, Endesfelder U, Mondry J, Gelleri M, Verveer PJ, Heilemann M. Coordinate-
14 based colocalization analysis of single-molecule localization microscopy data. *Histochem*
15 *Cell Biol*. 2012;137(1):1-10.
- 16 6. Ovesný M, Křížek P, Borkovec J, Svindrych Z, Hagen GM. ThunderSTORM: a
17 comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution
18 imaging. *Bioinformatics*. 2014;30(16):2389-2390.
- 19 7. Taylor KA, Wright JR, Vial C, Evans RJ, Mahaut-Smith MP. Amplification of human platelet
20 activation by surface pannexin-1 channels. *J Thromb Haemost*. 2014;12(6):987-998.
- 21 8. Vaiyapuri S, Jones CI, Sasikumar P, et al. Gap junctions and connexin hemichannels
22 underpin hemostasis and thrombosis. *Circulation*. 2012;125(20):2479-2491.
- 23 9. Lalo U, Allsopp RC, Mahaut-Smith MP, Evans RJ. P2X1 receptor mobility and trafficking;
24 regulation by receptor insertion and activation. *J Neurochem*. 2010;113(5):1177-1187.
- 25 10. Sayers EW, Cavanaugh M, Clark K, Ostell J, Pruitt KD, Karsch-Mizrachi I. GenBank. *Nucleic*
26 *Acids Res*. 2019;47(D1):D94-D99.
- 27 11. Wilkins MR, Gasteiger E, Bairoch A, et al. Protein identification and analysis tools in the
28 ExPASy server. *Methods Mol Biol*. 1999;112:531-552.
- 29 12. McGuffin LJ, Shuid AN, Kempster R, et al. Accurate template-based modeling in CASP12
30 using the IntFOLD4-TS, ModFOLD6, and ReFOLD methods. *Proteins*. 2018;86 Suppl 1:335-
31 344.
- 32 13. McGuffin LJ, Atkins JD, Salehe BR, Shuid AN, Roche DB. IntFOLD: an integrated server for
33 modelling protein structures and functions from amino acid sequences. *Nucleic Acids Res*.
34 2015;43(W1):W169-173.
- 35 14. Maghrabi AHA, McGuffin LJ. ModFOLD6: an accurate web server for the global and local
36 quality estimation of 3D protein models. *Nucleic Acids Res*. 2017;45(W1):W416-w421.

- 1 15. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web
2 service based on EADock DSS. *Nucleic Acids Res.* 2011;39(Web Server issue):W270-277.
- 3 16. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. *J*
4 *Mol Biol.* 2007;372(3):774-797.

5

6